A	O
series	O
of	O
2	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
-	O
1	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
benzimidazole	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acids	I-IUPAC
was	O
prepared	O
from	O
the	O
key	O
intermediate	O
3	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
(	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
benzoate	I-IUPAC
(	O
6a	O
-	O
c	O
)	O
in	O
order	O
to	O
clarify	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
various	O
analogues	O
of	O
2	B-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
tetrazol	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
biphenyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
ben	I-IUPAC
zimidazole	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
CV	O
-	O
11194	O
)	O
,	O
a	O
potent	O
and	O
long	O
acting	O
angiotensin	O
II	O
(	O
AII	O
)	O
receptor	O
antagonist	O
.	O
In	O
order	O
to	O
investigate	O
the	O
structural	O
requirements	O
for	O
gastroprotective	O
activity	O
in	O
6	B-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
1	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
benzopyran	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methylbutyl	I-IUPAC
]	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
,	I-IUPAC
5	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dihydroxy	I-IUPAC
6	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
3	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ammoniohexanoate	I-IUPAC
[	O
AI	O
-	O
77	O
-	O
B	O
,	O
1	O
]	O
,	O
a	O
product	O
of	O
Bacillus	O
pumilus	O
AI	O
-	O
77	O
,	O
nine	O
derivatives	O
were	O
prepared	O
and	O
then	O
tested	O
for	O
protective	O
activity	O
against	O
stress	O
-	O
induced	O
ulcers	O
in	O
rats	O
.	O
This	O
study	O
indicates	O
that	O
the	O
substitutions	O
with	O
none	O
or	O
low	O
polar	O
functional	O
groups	O
at	O
the	O
1	O
-	O
position	O
could	O
improve	O
the	O
selectivity	O
and	O
duration	O
of	O
the	O
bronchodilator	O
effects	O
of	O
xanthines	O
.	O
N	O
,	O
O	O
-	O
Dicarbethoxy	O
-	O
4	O
-	O
chlorobenzenesulfohydroxamate	O
(	O
1c	O
)	O
and	O
O	B-IUPAC
-	I-IUPAC
carbethoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
hydroxysaccharin	I-IUPAC
(	O
6	O
)	O
,	O
both	O
potential	O
carbethoxylating	O
agents	O
,	O
inhibited	O
yeast	O
aldehyde	O
dehydrogenase	O
(	O
AlDH	O
)	O
with	O
IC50	O
's	O
of	O
24	O
and	O
56	O
microM	O
,	O
respectively	O
.	O
N	O
-	O
Substituted	O
analogues	O
of	O
trans	B-PARTIUPAC
-	I-PARTIUPAC
7	I-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	B-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,4,4	I-IUPAC
a	I-IUPAC
,	I-IUPAC
5,6,10	I-IUPAC
b	I-IUPAC
-	I-IUPAC
octahydrobenzo	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
quinoline	I-IUPAC
(	O
trans	O
-	O
7	O
-	O
and	O
trans	O
-	O
9	O
-	O
OH	O
-	O
OHBQ	O
)	O
were	O
tested	O
for	O
dopamine	O
(	O
DA	O
)	O
D2	O
receptor	O
affinity	O
by	O
using	O
in	O
vitro	O
[	O
3H	O
]	O
spiperone	O
and	O
in	O
vivo	O
5,6	O
-	O
di	O
-	O
n	O
-	O
Pr	O
-	O
ADTN	O
binding	O
assays	O
.	O
In	O
contrast	O
with	O
type	O
I	O
mechanism	O
-	O
based	O
inactivation	O
,	O
reduction	O
of	O
enzyme	O
-	O
bound	O
NAD+	O
to	O
NADH	O
was	O
not	O
observed	O
.	O
The	O
X	O
-	O
ray	O
structures	O
show	O
that	O
both	O
complexes	O
have	O
a	O
pseudo	O
-	O
square	O
-	O
pyramidal	O
structure	O
of	O
[	O
RevO	O
]	O
3+	O
N2S2	O
core	O
with	O
oxygen	O
occupying	O
the	O
apical	O
position	O
and	O
the	O
N	O
-	O
alkyl	O
substitution	O
in	O
syn	O
-	O
configuration	O
to	O
the	O
oxo	O
-	O
rhenium	O
bond	O
.	O
We	O
hypothesized	O
that	O
the	O
lactam	O
ring	O
promoted	O
conformational	O
stability	O
to	O
yield	O
analogues	O
with	O
increased	O
potency	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
as	O
compared	O
to	O
that	O
of	O
their	O
linear	O
counterparts	O
.	O
1-9	O
)	O
,	O
a	O
75%	O
increase	O
in	O
survival	O
was	O
observed	O
relative	O
to	O
untreated	O
controls	O
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
any	O
host	O
toxicity	O
.	O
Additionally	O
,	O
we	O
monitored	O
the	O
dose	O
dependent	O
caspase	O
-	O
3	O
-	O
like	O
protease	O
activity	O
in	O
K562	O
cells	O
and	O
MCF	O
-	O
7	O
/	O
Casp	O
-	O
3	O
cells	O
treated	O
with	O
9h	O
,	O
indicating	O
induction	O
of	O
apoptosis	O
.	O
The	O
dibenzo	B-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
dioxin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxamides	I-IUPAC
are	O
active	O
against	O
wild	O
-	O
type	O
P388	O
leukemia	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
with	O
structure	O
-	O
activity	O
relationships	O
resembling	O
those	O
for	O
both	O
the	O
acridine	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
and	O
phenazine	B-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
series	B-MODIFIER
of	O
DNA	O
-	O
intercalating	O
antitumor	O
agents	O
.	O
Compounds	O
4	O
,	O
7	O
,	O
and	O
15	O
were	O
designed	O
as	O
putative	O
substrates	O
of	O
the	O
"	O
hydrolytic	O
activity	O
"	O
of	O
S	B-IUPAC
-	I-IUPAC
adenosyl	I-IUPAC
-	I-IUPAC
l	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
(	O
AdoHcy	O
)	O
hydrolase	O
.	O
The	O
products	O
were	O
tested	O
for	O
in	O
vivo	O
antitumor	O
activity	O
against	O
L1210	O
leukemia	O
in	O
mice	O
to	O
test	O
whether	O
all	O
MTX	O
and	O
DCM	O
diesters	O
are	O
therapeutically	O
equivalent	O
in	O
this	O
species	O
.	O
The	O
contractile	O
effects	O
on	O
guinea	O
pig	O
ileum	O
and	O
aorta	O
,	O
respectively	O
,	O
could	O
be	O
blocked	O
concentration	O
-	O
dependently	O
by	O
the	O
H1	O
receptor	O
antagonist	O
mepyramine	O
,	O
yielding	O
KB	O
values	O
for	O
mepyramine	O
in	O
the	O
nanomolar	O
range	O
.	O
All	O
compounds	O
showed	O
high	O
affinity	O
for	O
the	O
DAT	O
.	O
On	O
the	O
basis	O
of	O
inhibition	O
of	O
HIV	O
-	O
1'	O
s	O
cytopathic	O
effects	O
in	O
MT	O
-	O
4	O
cells	O
,	O
we	O
found	O
that	O
5	O
-	O
mono	O
-	O
Me	O
-	O
substituted	O
analogues	O
,	O
the	O
original	O
substitution	O
in	O
the	O
early	O
lead	O
compounds	O
,	O
and	O
7	O
-	O
mono	O
-	O
Me	O
-	O
substituted	O
analogues	O
of	O
1	O
were	O
comparable	O
as	O
being	O
consistently	O
the	O
most	O
active	O
compounds	O
.	O
The	O
enantiomers	O
of	O
(	O
fluoroalkyl	O
)	O
benzilic	O
acids	O
were	O
prepared	O
via	O
an	O
enantioselective	O
Grignard	O
addition	O
reaction	O
.	O
Although	O
2	B-IUPAC
-	I-IUPAC
oxoadenosine	I-IUPAC
is	O
3	O
times	O
more	O
vasoactive	O
than	O
2	B-IUPAC
-	I-IUPAC
aminoadenosine	I-IUPAC
,	O
the	O
activities	O
of	O
the	O
phenyl	B-IUPAC
derivatives	B-MODIFIER
are	O
markedly	O
different	O
;	O
2	B-IUPAC
-	I-IUPAC
phenoxyadenosine	I-IUPAC
is	O
23	O
times	O
weaker	O
than	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
(	O
CV	O
-	O
1808	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
The	O
synthesis	O
and	O
alpha	O
2	O
-	O
adrenergic	O
activity	O
of	O
a	O
series	O
of	O
indolin	B-PARTIUPAC
-	I-PARTIUPAC
2	I-PARTIUPAC
-	I-PARTIUPAC
yl	I-PARTIUPAC
and	O
tetrahydroquinolin	B-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
imidazolines	I-IUPAC
are	O
described	O
.	O
In	O
this	O
experimental	O
system	O
,	O
recovery	O
from	O
hypoglycemia	O
proceeded	O
with	O
a	O
t	O
(	O
1/2	O
)	O
value	O
of	O
14	O
+	O
/	O
-	O
1	O
h	O
,	O
as	O
compared	O
with	O
t	O
(	O
1/2	O
)	O
=	O
8.0	O
+	O
/	O
-	O
1	O
h	O
for	O
native	O
insulin	O
and	O
t	O
(	O
1/2	O
)	O
=	O
10.0	O
+	O
/	O
-	O
1	O
h	O
for	O
NPH	O
-	O
insulin	O
.	O
The	O
results	O
presented	O
in	O
this	O
article	O
point	O
to	O
the	O
utility	O
of	O
1	B-IUPAC
-	I-IUPAC
hydroxypyrazole	I-IUPAC
and	O
1,2,3	B-IUPAC
-	I-IUPAC
hydroxytriazole	I-IUPAC
as	O
bioisosteres	O
of	O
carboxylic	O
acids	O
at	O
Glu	O
receptors	O
and	O
transporters	O
.	O
The	O
stereochemical	O
diversity	O
-	O
oriented	O
conformational	O
restriction	O
strategy	O
can	O
be	O
an	O
efficient	O
method	O
for	O
developing	O
specific	O
ligands	O
for	O
drug	O
target	O
proteins	O
,	O
especially	O
in	O
cases	O
where	O
neither	O
the	O
bioactive	O
conformation	O
nor	O
the	O
pharmacophore	O
is	O
known	O
.	O
However	O
,	O
the	O
present	O
results	O
,	O
together	O
with	O
the	O
previous	O
,	O
demonstrate	O
that	O
8a	O
and	O
8b	O
are	O
promising	O
new	O
prodrugs	O
of	O
ara	O
-	O
C	O
with	O
improved	O
efficacy	O
.	O
Our	O
findings	O
revealed	O
that	O
the	O
optimal	O
stereochemical	O
array	O
was	O
the	O
same	O
for	O
both	O
NMDA	O
(	O
32	O
and	O
61	O
)	O
and	O
AMPA	O
(	O
9	O
)	O
antagonists	O
identified	O
in	O
this	O
series	O
and	O
that	O
the	O
tetrahydroisoquinoline	O
(	O
25	O
)	O
and	O
the	O
C	B-MODIFIER
-	I-MODIFIER
1	I-MODIFIER
carboxy	B-IUPAC
(	O
30	O
)	O
analogs	B-MODIFIER
of	O
9	O
are	O
inactive	O
.	O
Several	O
compounds	O
prolonged	O
the	O
survival	O
time	O
of	O
mice	O
in	O
hypoxic	O
conditions	O
at	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
(	O
sc	O
or	O
ip	O
)	O
and	O
100	O
mg	O
/	O
kg	O
(	O
po	O
)	O
.	O
A	O
series	O
of	O
dialkyl	B-MODIFIER
N	B-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
m	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamates	I-IUPAC
was	O
synthesized	O
by	O
treatment	O
of	O
the	O
requisite	O
m	B-IUPAC
-	I-IUPAC
phenylenediamines	I-IUPAC
with	O
an	O
alkyloxalyl	O
chloride	O
in	O
the	O
presence	O
of	O
triethylamine	O
.	O
(	B-IUPAC
m	I-IUPAC
-	I-IUPAC
[	I-IUPAC
125I	I-IUPAC
]	I-IUPAC
Iodobenzyl	I-IUPAC
)	I-IUPAC
guanidine	I-IUPAC
(	O
m	O
-	O
IBG	O
,	O
2b	O
)	O
gave	O
the	O
best	O
combination	O
of	O
high	O
concentration	O
and	O
selectivity	O
.	O
N	O
-	O
Methylation	O
reduced	O
affinity	O
greatly	O
as	O
did	O
increasing	O
the	O
size	O
of	O
the	O
acyl	O
moiety	O
.	O
After	O
aromatization	O
,	O
these	O
compounds	O
were	O
transformed	O
by	O
phosphorus	O
oxychloride	O
,	O
giving	O
1	B-PARTIUPAC
-	I-PARTIUPAC
chloro	I-PARTIUPAC
-	I-PARTIUPAC
4	I-PARTIUPAC
-	I-PARTIUPAC
methyl	I-PARTIUPAC
-	I-PARTIUPAC
5H	I-PARTIUPAC
-	I-PARTIUPAC
pyrido	I-PARTIUPAC
[	I-PARTIUPAC
4,3	I-PARTIUPAC
-	I-PARTIUPAC
b	I-PARTIUPAC
]	I-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
e	I-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
and	O
-	B-PARTIUPAC
benzo	I-PARTIUPAC
[	I-PARTIUPAC
g	I-PARTIUPAC
]	I-PARTIUPAC
indoles	I-PARTIUPAC
which	O
were	O
substituted	O
by	O
[	B-IUPAC
(	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
amines	I-IUPAC
.	O
Extension	O
of	O
the	O
2	B-IUPAC
-	I-IUPAC
phenylamino	I-IUPAC
group	B-MODIFIER
to	O
2	B-PARTIUPAC
-	I-PARTIUPAC
benzyl	I-PARTIUPAC
-	I-PARTIUPAC
and	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethylamino	I-IUPAC
)	I-IUPAC
reduced	O
affinity	O
.	O
Conventional	O
functional	O
group	O
transformation	O
of	O
5a	O
and	O
5b	O
provided	O
a	O
number	O
of	O
novel	O
3	O
-	O
substituted	O
allopurinol	O
nucleosides	O
,	O
which	O
included	O
10a	O
and	O
18a	O
-	O
d	O
.	O
In	O
this	O
fashion	O
,	O
5	B-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
(	O
or	O
more	O
appropriately	O
,	O
6	B-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthoic	I-IUPAC
acid	I-IUPAC
)	O
has	O
been	O
identified	O
as	O
a	O
novel	O
PTP1B	O
binding	O
motif	O
.	O
The	O
pA2	O
values	O
were	O
8.20	O
(	O
1	O
)	O
,	O
6.40	O
(	O
2	O
)	O
,	O
6.20	O
(	O
3	O
)	O
,	O
6.25	O
(	O
4	O
)	O
,	O
6.30	O
(	O
5	O
)	O
,	O
6.30	O
(	O
7	O
)	O
,	O
6.05	O
(	O
8	O
)	O
,	O
6.20	O
(	O
9	O
)	O
,	O
6.30	O
(	O
10	O
)	O
,	O
6.25	O
(	O
11	O
)	O
,	O
6.10	O
(	O
12	O
)	O
,	O
6.20	O
(	O
13	O
)	O
,	O
6.20	O
(	O
14	O
)	O
,	O
and	O
6.35	O
(	O
15	O
)	O
.	O
These	O
compounds	O
did	O
not	O
bind	O
to	O
the	O
BZP	O
receptor	O
in	O
spite	O
of	O
having	O
structures	O
similar	O
to	O
those	O
of	O
beta	O
-	O
carbolines	O
.	O
The	O
corresponding	O
diamino	O
acids	O
were	O
obtained	O
from	O
the	O
diamines	O
and	O
oxocarboxylic	O
acids	O
by	O
catalytic	O
hydrogenation	O
.	O
Escherichia	O
coli	O
TK	O
was	O
inactivated	O
by	O
6	O
of	O
25	O
ATP	O
derivatives	O
tested	O
at	O
10	O
mM	O
,	O
6	O
h	O
,	O
0	O
degrees	O
C	O
;	O
inactivation	O
was	O
slowed	O
by	O
MgATP	O
in	O
the	O
case	O
of	O
N6	O
-	O
CH3	O
-	O
N6	O
-	O
R	O
-	O
ATP	O
[	O
R	O
=	O
(	O
CH2	O
)	O
4N	O
(	O
CH3	O
)	O
CO	O
(	O
CH2	O
)	O
5NHCOCH2I	O
]	O
.	O
The	O
p	B-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
-	O
substituted	B-MODIFIER
derivatives	B-MODIFIER
11	O
and	O
27	O
(	O
APPPI	O
)	O
may	O
be	O
interesting	O
pharmacological	O
tools	O
due	O
to	O
their	O
fluorescent	O
properties	O
.	O
The	O
racemate	O
and	O
the	O
enantiomers	B-MODIFIER
of	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminopropane	I-IUPAC
(	O
6	O
)	O
and	O
racemic	B-MODIFIER
5	B-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoindan	I-IUPAC
(	O
11	O
)	O
were	O
tested	O
for	O
stimulus	O
generalization	O
in	O
the	O
two	O
-	O
lever	O
drug	O
-	O
discrimination	O
paradigm	O
.	O
The	O
potency	O
and	O
selectivity	O
(	O
delta	O
vs	O
mu	O
opioid	O
receptor	O
)	O
were	O
evaluated	O
by	O
radioreceptor	O
binding	O
assays	O
in	O
the	O
rat	O
brain	O
using	O
[	O
3H	O
]	O
CTOP	O
(	O
mu	O
ligand	O
)	O
and	O
[	O
3H	O
]	O
DPDPE	O
(	O
delta	O
ligand	O
)	O
and	O
by	O
bioassay	O
with	O
mouse	O
vas	O
deferens	O
(	O
MVD	O
,	O
delta	O
receptor	O
assay	O
)	O
and	O
guinea	O
pig	O
ileum	O
(	O
GPI	O
,	O
mu	O
receptor	O
assay	O
)	O
.	O
Treatment	O
of	O
the	O
imidate	O
(	O
4	O
)	O
with	O
sodium	O
hydrogen	O
sulfide	O
gave	O
the	O
thiocarboxamide	B-IUPAC
derivative	B-MODIFIER
5	O
.	O
However	O
,	O
in	O
biological	O
investigations	O
using	O
a	O
subcutaneous	O
B16	O
(	O
hypoxic	O
)	O
melanoma	O
tumor	O
in	O
BDF1	O
hybrid	O
mice	O
with	O
cyclophosphamide	O
as	O
positive	O
control	O
the	O
most	O
interesting	O
series	O
of	O
structurally	O
related	O
analogues	O
were	O
the	O
potentially	O
monoalkylating	O
monoquinones	O
of	O
the	O
2	B-PARTIUPAC
-	I-PARTIUPAC
[	I-PARTIUPAC
(	O
leaving	O
group	O
)	O
methyl	B-PARTIUPAC
]	I-PARTIUPAC
-	I-PARTIUPAC
1,4	I-PARTIUPAC
-	I-PARTIUPAC
benzoquinone	I-PARTIUPAC
type	B-MODIFIER
(	O
i.e.	O
,	O
14	O
and	O
15	O
)	O
having	O
water	O
-	O
insoluble	O
(	O
acetoxy	O
)	O
and	O
water	O
-	O
solubilizing	O
(	O
succinate	O
)	O
groups	O
.	O
Assessment	O
of	O
the	O
dopaminergic	O
activity	O
of	O
these	O
catechols	O
and	O
the	O
results	O
from	O
the	O
determination	O
of	O
brain	O
levels	O
of	O
the	O
enantiomers	O
of	O
3	O
-	O
PPP	O
and	O
their	O
metabolites	O
indicate	O
that	O
the	O
metabolites	O
probably	O
do	O
not	O
alter	O
the	O
pharmacological	O
profiles	O
established	O
for	O
(	O
R	O
)	O
-	O
(	O
+	O
)	O
-	O
and	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
3	O
-	O
PPP	O
.	O
Methods	O
have	O
been	O
developed	O
for	O
the	O
preparation	O
of	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
(	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
aminopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
iodothiophenes	I-IUPAC
.	O
Treatment	O
of	O
1,2	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxopyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
5	O
)	O
with	O
phosgene	O
in	O
THF	O
solution	O
gives	O
the	O
active	O
ester	O
poly	B-IUPAC
[	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dioxopyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
]	I-IUPAC
,	O
which	O
upon	O
treatment	O
with	O
excess	O
anhydrous	O
dimethylamine	O
gave	O
a	O
60%	O
yield	O
of	O
N	B-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1,2	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxopyridine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
(	O
6	O
)	O
.	O
Reaction	O
of	O
5	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
with	O
2	B-IUPAC
-	I-IUPAC
acetoxyethyl	I-IUPAC
acetoxymethyl	I-IUPAC
ether	I-IUPAC
and	O
SnCl4	O
,	O
followed	O
by	O
ammonolysis	O
,	O
yielded	O
5	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
cytosine	I-IUPAC
(	O
12	O
)	O
.	O
The	O
affinity	O
of	O
the	O
compounds	O
for	O
the	O
GABA	O
receptors	O
and	O
for	O
the	O
neuronal	O
(	O
synaptosomal	O
)	O
GABA	O
uptake	O
system	O
in	O
vitro	O
has	O
been	O
measured	O
.	O
gondii	O
infection	O
in	O
mice	O
when	O
given	O
qdx8	O
by	O
peritoneal	O
injection	O
at	O
doses	O
ranging	O
from	O
62.5	O
(	O
initial	O
dose	O
)	O
to	O
25	O
mg	O
/	O
kg	O
.	O
The	O
aim	O
of	O
this	O
project	O
was	O
to	O
further	O
investigate	O
whether	O
it	O
is	O
possible	O
to	O
differentiate	O
between	O
these	O
compounds	O
with	O
respect	O
to	O
their	O
affinity	O
for	O
alpha	O
(	O
1	O
)	O
-	O
adrenoreceptor	O
subtypes	O
and	O
the	O
affinity	O
for	O
5	O
-	O
HT	O
(	O
1A	O
)	O
receptors	O
,	O
as	O
1	O
binds	O
with	O
high	O
affinity	O
at	O
both	O
receptor	O
systems	O
.	O
The	O
compounds	O
were	O
screened	O
as	O
potential	O
H1	O
receptor	O
agonists	O
on	O
the	O
isolated	O
guinea	O
pig	O
ileum	O
.	O
Five	O
compounds	O
exhibited	O
inhibitory	O
activity	O
in	O
the	O
same	O
range	O
as	O
the	O
standards	O
,	O
4	B-IUPAC
-	I-IUPAC
hydroxypyrazolo	I-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
and	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
trifluoromethylimidazole	I-IUPAC
(	O
22	O
)	O
.	O
Carboxylic	O
acid	O
esters	O
(	O
9-11	O
,	O
14-16	O
,	O
27-29	O
)	O
and	O
a	O
cyclic	O
phosphate	O
derivative	O
(	O
22	O
)	O
of	O
the	O
9	B-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkoxy	I-IUPAC
)	I-IUPAC
guanines	I-IUPAC
(	O
8	O
,	O
21	O
)	O
and	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkoxy	I-IUPAC
)	I-IUPAC
purines	I-IUPAC
(	O
13	O
,	O
26	O
)	O
were	O
also	O
prepared	O
.	O
3	B-IUPAC
-	I-IUPAC
Ethoxy	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
H	I-IUPAC
-	I-IUPAC
cyclopenta	I-IUPAC
[	I-IUPAC
f	I-IUPAC
]	I-IUPAC
isoquinoline	I-IUPAC
(	O
4	O
)	O
which	O
constitutes	O
the	O
basic	O
ring	O
system	O
of	O
1	O
was	O
synthesized	O
in	O
a	O
multistep	O
procedure	O
starting	O
from	O
m	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
acetylbenzylamine	I-IUPAC
(	O
5	O
)	O
.	O
8	O
-	O
Carbamoyl	O
-	O
3	O
-	O
methylimidazo	O
[	O
5,1	O
-	O
d	O
]	O
-	O
1,2,3,5	O
-	O
tetrazin	O
-	O
4	O
(	O
3H	O
)	O
-	O
one	O
(	O
temozolomide	O
,	O
1	O
)	O
is	O
an	O
anticancer	O
prodrug	O
.	O
For	O
analysis	O
of	O
uPAR	O
binding	O
activity	O
,	O
we	O
employed	O
competitive	O
flow	O
cytofluorometric	O
receptor	O
binding	O
assays	O
,	O
using	O
FITC	O
-	O
uPA	O
as	O
the	O
ligand	O
and	O
U937	O
promyeloid	O
leukemia	O
cells	O
as	O
the	O
cellular	O
source	O
of	O
uPAR	O
.	O
Acids	O
1a	O
and	O
1c	O
were	O
the	O
most	O
active	O
heteroarotinoids	O
in	O
the	O
two	O
biological	O
assays	O
.	O
In	O
mouse	O
plasma	O
,	O
1c	O
was	O
degraded	O
first	O
to	O
FdUMP	O
and	O
then	O
to	O
FUdR	O
.	O
This	O
concept	O
takes	O
advantage	O
of	O
the	O
cytotoxic	O
properties	O
of	O
AEL	O
drugs	O
as	O
well	O
as	O
the	O
membrane	O
permeability	O
enhancing	O
properties	O
of	O
these	O
molecules	O
,	O
which	O
can	O
lead	O
to	O
enhanced	O
drug	O
diffusion	O
into	O
cells	O
.	O
In	O
a	O
comparative	O
study	O
the	O
benzopyran	O
16	O
was	O
found	O
to	O
be	O
more	O
effective	O
antiestrogen	O
than	O
tamoxifen	O
while	O
being	O
as	O
effective	O
as	O
LY	O
-	O
117018	O
.	O
In	O
this	O
paper	O
we	O
describe	O
the	O
synthesis	O
of	O
a	O
series	O
of	O
novel	O
2	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
alkylsemicarbazono	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
methylenedioxyphenylacetic	I-IUPAC
acid	I-IUPAC
alkyl	I-IUPAC
esters	I-IUPAC
(	O
10-19	O
)	O
carrying	O
an	O
alkylsemicarbazono	O
moiety	O
at	O
a	O
benzylic	O
site	O
.	O
Structure	O
-	O
-	O
activity	O
relationships	O
suggest	O
that	O
a	O
proton	O
at	O
the	O
C	O
-	O
1	O
position	O
appears	O
necessary	O
for	O
agonist	O
activity	O
and	O
the	O
acidity	O
of	O
this	O
proton	O
has	O
a	O
relatively	O
greater	O
influence	O
on	O
activity	O
than	O
pendant	O
steric	O
bulk	O
.	O
The	O
design	O
of	O
analogues	O
of	O
7,8	B-IUPAC
-	I-IUPAC
dihydroretinoic	I-IUPAC
acid	I-IUPAC
(	O
7,8	O
-	O
dihydro	O
-	O
RA	O
)	O
was	O
based	O
on	O
reported	O
biological	O
activities	O
of	O
this	O
retinoid	O
and	O
its	O
dihydro	O
-	O
TMMP	O
(	O
1	O
)	O
analogue	O
and	O
on	O
structural	O
hypotheses	O
.	O
Moreover	O
,	O
its	O
cerebral	O
uptake	O
can	O
be	O
modulated	O
by	O
the	O
synaptic	O
concentration	O
of	O
the	O
endogenous	O
ligand	O
acetylcholine	O
.	O
Instead	O
,	O
they	O
behaved	O
as	O
classic	O
inhibitors	O
of	O
tritium	O
release	O
from	O
[	O
5	O
-	O
(	O
3	O
)	O
H	O
]	O
dUMP	O
.	O
In	O
addition	O
,	O
AT2	O
binding	O
for	O
some	O
of	O
these	O
compounds	O
was	O
increased	O
by	O
as	O
much	O
as	O
1000	O
-	O
fold	O
over	O
the	O
corresponding	O
tetrazole	O
(	O
e.g.	O
,	O
AT2	O
IC50	O
17	O
nM	O
for	O
the	O
tert	B-IUPAC
-	I-IUPAC
butyl	I-IUPAC
sulfonylcarbamate	I-IUPAC
92	O
)	O
.	O
The	O
thione	O
11	O
rearranges	O
to	O
N	B-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
[	I-IUPAC
1,2,3	I-IUPAC
]	I-IUPAC
thiadiazolo	I-IUPAC
[	I-IUPAC
5,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
(	O
14	O
)	O
in	O
the	O
solid	O
state	O
or	O
in	O
solution	O
.	O
5'	B-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Pivaloyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
dioxaphosphorinan	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouridine	I-IUPAC
(	O
1c	O
)	O
was	O
designed	O
as	O
a	O
potential	O
membrane	O
-	O
permeable	O
prodrug	O
of	O
2'	B-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouridine	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
monophosphate	I-IUPAC
(	O
FdUMP	O
)	O
,	O
a	O
putative	O
active	O
metabolite	O
of	O
the	O
antitumor	O
drug	O
5	B-IUPAC
-	I-IUPAC
fluorouracil	I-IUPAC
(	O
FU	O
)	O
.	O
2,3	B-IUPAC
-	I-IUPAC
Dimethylputrescine	I-IUPAC
however	O
,	O
was	O
transported	O
into	O
the	O
cells	O
and	O
significantly	O
decreased	O
its	O
ODC	O
activity	O
.	O
Chloro	B-IUPAC
derivatives	B-MODIFIER
2e	O
-	O
g	O
,	O
4c	O
-	O
f	O
,	O
5d	O
,	O
and	O
6c	O
-	O
e	O
as	O
well	O
as	O
pyrimidine	O
oxacyclopentenes	O
9c	O
and	O
9d	O
are	O
slow	O
-	O
acting	O
inhibitors	O
of	O
murine	O
leukemia	O
L1210	O
of	O
IC50	O
10-100	O
microM	O
.	O
With	O
some	O
preliminary	O
optimization	O
,	O
the	O
A2a	O
binding	O
affinity	O
of	O
some	O
of	O
the	O
best	O
piperazine	O
derivatives	O
is	O
almost	O
as	O
good	O
as	O
that	O
of	O
compound	O
3	O
.	O
The	O
total	O
synthesis	O
time	O
was	O
50-53	O
min	O
from	O
the	O
end	O
of	O
cyclotron	O
fluorine	O
-	O
18	O
production	O
(	O
EOB	O
)	O
.	O
The	O
results	O
suggest	O
a	O
possible	O
way	O
of	O
combining	O
a	O
drug	O
-	O
delivery	O
and	O
prodrug	O
concept	O
in	O
a	O
single	O
liposome	O
system	O
.	O
Finally	O
,	O
binding	O
assays	O
performed	O
with	O
selected	O
quinazolines	O
(	O
2	O
,	O
3	O
,	O
and	O
14	O
)	O
produced	O
affinity	O
results	O
,	O
which	O
were	O
not	O
in	O
agreement	O
with	O
the	O
selectivity	O
profiles	O
obtained	O
from	O
functional	O
experiments	O
.	O
The	O
presence	O
of	O
a	O
6	O
-	O
substituent	O
containing	O
an	O
aryl	O
group	O
appeared	O
to	O
be	O
necessary	O
for	O
activity	O
,	O
which	O
was	O
increased	O
when	O
a	O
methyl	B-IUPAC
group	I-IUPAC
was	O
substituted	B-MODIFIER
at	O
the	O
7	O
-	O
position	O
.	O
As	O
part	O
of	O
our	O
investigation	O
into	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
a	O
novel	O
class	O
of	O
aromatase	O
inhibitors	O
,	O
C	O
(	O
19	O
)	O
steroids	O
having	O
no	O
oxygen	O
function	O
at	O
C	O
-	O
3	O
,	O
we	O
tested	O
aromatase	O
inhibition	O
activity	O
of	O
polar	O
diol	O
compounds	O
4,19	B-IUPAC
-	I-IUPAC
dihydroxyandrost	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
25	O
and	O
27	O
)	O
and	O
6,19	B-IUPAC
-	I-IUPAC
dihydroxyandrost	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
en	I-IUPAC
-	I-IUPAC
17	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
36	O
and	O
37	O
)	O
.	O
None	O
of	O
the	O
N	B-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phosphonomethoxy	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
isomers	B-MODIFIER
exhibited	O
any	O
antiviral	O
activity	O
against	O
DNA	O
viruses	O
or	O
RNA	O
viruses	O
tested	O
in	O
vitro	O
.	O
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
Pentazocine	I-IUPAC
[	O
(	O
-	O
)	O
-	O
1b	O
]	O
and	O
its	O
2'	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
analogue	B-MODIFIER
,	O
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylallyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5,9	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
benzomorphan	I-IUPAC
[	O
(	O
-	O
)	O
-	O
4a	O
]	O
showed	O
the	O
highest	O
potency	O
for	O
the	O
sigma	O
2	O
binding	O
site	O
.	O
Lu	O
29-253	O
)	O
.	O
Hydrogen	O
bonding	O
is	O
hereby	O
gradually	O
replaced	O
by	O
van	O
der	O
Waals	O
interactions	O
involving	O
a	O
relatively	O
large	O
lipophilic	O
pocket	O
.	O
The	O
key	O
intermediate	O
was	O
the	O
protected	O
nonapeptide	O
N	B-IUPAC
-	I-IUPAC
carbobenzoxy	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
cysteinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
tyrosyldihydrophenyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
alanyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
glutaminyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
asparaginyl	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
cysteinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
prolyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
epsilon	I-IUPAC
-	I-IUPAC
tosyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
lysylglycinamide	I-IUPAC
that	O
was	O
synthesized	O
stepwise	O
by	O
the	O
solid	O
-	O
phase	O
technique	O
.	O
In	O
the	O
series	O
of	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylamino	I-IUPAC
)	I-IUPAC
,	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
phenyloxy	I-IUPAC
)	I-IUPAC
,	O
and	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylthio	I-IUPAC
)	I-IUPAC
substitutions	B-MODIFIER
,	O
the	O
order	O
of	O
affinity	O
at	O
the	O
A	O
(	O
3	O
)	O
AR	O
was	O
oxy	O
&	O
gt	O
;	O
or	O
=	O
amino	O
&	O
gt	O
;	O
thio	O
.	O
Such	O
chemical	O
and	O
biological	O
characteristics	O
of	O
MIH	O
would	O
enable	O
high	O
target	O
/	O
nontarget	O
ratios	O
in	O
diagnostic	O
and	O
therapeutic	O
nuclear	O
medicine	O
using	O
mAbs	O
and	O
other	O
polypeptides	O
.	O
On	O
the	O
basis	O
of	O
surface	O
area	O
of	O
the	O
bromine	O
atom	O
,	O
this	O
value	O
is	O
2-3	O
times	O
higher	O
than	O
would	O
be	O
expected	O
on	O
the	O
basis	O
of	O
hydrophobic	O
binding	O
.	O
They	O
are	O
thus	O
nonselective	O
oxytocin	O
antagonists	O
.	O
Most	O
compounds	O
displayed	O
low	O
micromolar	O
antitrypanosomal	O
activity	O
,	O
with	O
five	O
of	O
them	O
presenting	O
a	O
nanomolar	O
inhibitory	O
action	O
on	O
the	O
parasite	O
:	O
1,9	B-IUPAC
-	I-IUPAC
nonanediguanidine	I-IUPAC
(	O
1c	O
)	O
,	O
1,12	B-IUPAC
-	I-IUPAC
dodecanediguanidine	I-IUPAC
(	O
1d	O
)	O
,	O
4,4	B-IUPAC
'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
[	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
imidazolidinylimino	I-IUPAC
]	I-IUPAC
diphenylamine	I-IUPAC
(	O
28a	O
)	O
,	O
4,4	B-IUPAC
'	I-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
imidazolylamino	I-IUPAC
)	I-IUPAC
diphenylamine	I-IUPAC
(	O
28b	O
)	O
,	O
and	O
4,4	B-IUPAC
'	I-IUPAC
-	I-IUPAC
diguanidinodiphenylamine	I-IUPAC
(	O
32b	O
)	O
.	O
Intriguingly	O
,	O
it	O
was	O
demonstrated	O
in	O
vivo	O
that	O
5a	O
suppressed	O
the	O
SP	O
-	O
induced	O
bronchoconstriction	O
and	O
airway	O
edema	O
in	O
guinea	O
pigs	O
with	O
ED50	O
of	O
0.42	O
mg	O
/	O
kg	O
and	O
0.66	O
mg	O
/	O
kg	O
,	O
respectively	O
,	O
when	O
administered	O
intravenously	O
.	O
Although	O
their	O
affinities	O
for	O
the	O
estrogen	O
receptor	O
were	O
very	O
low	O
(	O
from	O
0.008%	O
to	O
0.02%	O
that	O
of	O
estradiol	O
)	O
,	O
they	O
appeared	O
to	O
be	O
efficient	O
affinity	O
labels	O
of	O
the	O
receptor	O
due	O
to	O
their	O
irreversible	O
inhibition	O
of	O
[	B-IUPAC
3H	I-IUPAC
]	I-IUPAC
estradiol	I-IUPAC
specific	O
binding	O
in	O
lamb	O
uterine	O
cytosol	O
.	O
The	O
syntheses	O
of	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
(	O
9	O
,	O
ATPA	O
)	O
,	O
(	B-IUPAC
alpha	I-IUPAC
-	I-IUPAC
RS	I-IUPAC
,	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
(	O
8	O
)	O
,	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isoxazolebutyric	I-IUPAC
acid	I-IUPAC
(	O
15a	O
)	O
,	O
and	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
isoxazolevaleric	I-IUPAC
acid	I-IUPAC
(	O
15b	O
)	O
are	O
described	O
.	O
The	O
most	O
interesting	O
effect	O
of	O
hydroxylating	O
CPMENSPM	O
is	O
the	O
profound	O
reduction	O
in	O
toxicity	O
compared	O
with	O
that	O
of	O
the	O
parent	O
drug	O
.	O
The	O
structure	O
of	O
the	O
obtained	O
compounds	O
was	O
proved	O
by	O
1H	O
NMR	O
UV	O
,	O
13C	O
NMR	O
,	O
and	O
CD	O
spectroscopy	O
,	O
as	O
well	O
as	O
elemental	O
(	O
C	O
,	O
H	O
,	O
N	O
)	O
analysis	O
.	O
The	O
activities	O
of	O
the	O
24	O
-	O
one	O
and	O
delta	O
(	O
22	O
)	O
-	O
24	O
-	O
one	O
compounds	O
were	O
expected	O
to	O
be	O
very	O
low	O
,	O
because	O
the	O
carbonyl	B-IUPAC
group	B-MODIFIER
in	O
these	O
compounds	O
is	O
located	O
over	O
the	O
steroid	O
C	O
-	O
ring	O
and	O
oriented	O
toward	O
C	O
-	O
8	O
.	O
The	O
non	O
-	O
nucleoside	O
nitrile	O
analogs	O
4a	O
-	O
m	O
and	O
carboxamide	B-IUPAC
derivatives	B-MODIFIER
5a	O
-	O
l	O
were	O
,	O
with	O
a	O
few	O
exceptions	O
,	O
essentially	O
inactive	O
against	O
HCMV	O
and	O
HSV	O
-	O
1	O
and	O
relatively	O
nontoxic	O
.	O
None	O
of	O
the	O
compounds	O
exhibiting	O
in	O
vitro	O
activity	O
were	O
active	O
against	O
S	O
.	O
Regioselective	O
alkylation	O
of	O
tris	B-IUPAC
(	I-IUPAC
trimethylsilyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
aminouracil	I-IUPAC
provides	O
3	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
6	B-IUPAC
-	I-IUPAC
aminouracils	I-IUPAC
,	O
which	O
are	O
converted	O
to	O
1,8	B-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
xanthines	B-IUPAC
by	O
standard	O
procedures	O
.	O
Enzyme	O
inhibition	O
assays	O
against	O
rat	O
liver	O
DHFR	O
,	O
Pneumocystis	O
carinii	O
DHFR	O
,	O
and	O
the	O
bifunctional	O
DHFR	O
-	O
TS	O
enzyme	O
from	O
Toxoplasma	O
gondii	O
were	O
carried	O
out	O
,	O
and	O
the	O
selectivity	O
ratios	O
IC50	O
(	O
rat	O
)	O
/	O
IC50	O
(	O
P	O
.	O
Oxidation	O
using	O
tert	B-IUPAC
-	I-IUPAC
butyl	I-IUPAC
hydroperoxide	I-IUPAC
gave	O
2,5,6	B-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
1,3,4	I-IUPAC
-	I-IUPAC
tris	I-IUPAC
(	I-IUPAC
dibenzylphospho	I-IUPAC
)	I-IUPAC
-	I-IUPAC
myo	I-IUPAC
-	I-IUPAC
inositol	I-IUPAC
,	O
and	O
deprotection	O
using	O
sodium	O
in	O
liquid	O
ammonia	O
gave	O
racemic	B-MODIFIER
myo	B-IUPAC
-	I-IUPAC
inositol	I-IUPAC
1,3,4	I-IUPAC
-	I-IUPAC
trisphosphate	I-IUPAC
.	O
Reductive	O
deamination	O
of	O
compounds	O
1a	O
-	O
k	O
provides	O
the	O
2	B-IUPAC
-	I-IUPAC
quinoxalinecarbonitriles	I-IUPAC
5a	O
-	O
k	O
,	O
which	O
are	O
more	O
potent	O
,	O
while	O
selectivity	O
is	O
maintained	O
or	O
increased	O
in	O
some	O
derivatives	O
.	O
Whereas	O
dihydropyridine	O
enantiomers	O
usually	O
show	O
10-15	O
-	O
fold	O
difference	O
in	O
activity	O
,	O
the	O
enantiomers	O
of	O
dihydropyrimidine	O
3j	O
show	O
more	O
than	O
a	O
1000	O
-	O
fold	O
difference	O
in	O
activity	O
.	O
All	O
of	O
the	O
compounds	O
studied	O
displayed	O
lower	O
affinity	O
for	O
PNMT	O
than	O
1	O
,	O
and	O
nine	O
of	O
the	O
eleven	O
compounds	O
studied	O
showed	O
increased	O
,	O
rather	O
than	O
the	O
desired	O
decreased	O
,	O
affinity	O
for	O
the	O
alpha	O
2	O
-	O
adrenoceptor	O
.	O
Synthesis	O
of	O
2	B-IUPAC
-	I-IUPAC
[	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
amino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
benzoxazaphosphorin	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
2	O
)	O
,	O
which	O
is	O
a	O
benzo	O
annulated	O
analog	O
of	O
cyclophosphamide	O
[	O
2	B-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloroethyl	I-IUPAC
)	I-IUPAC
aminotetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
oxazaphosphorin	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxide	I-IUPAC
(	O
1	O
)	O
]	O
,	O
was	O
carried	O
out	O
in	O
order	O
to	O
test	O
for	O
possible	O
increased	O
antitumor	O
activity	O
relative	O
to	O
1	O
due	O
to	O
the	O
presence	O
of	O
an	O
oxidatively	O
reactive	O
C	O
-	O
4	O
benzylic	O
site	O
in	O
2	O
.	O
The	O
monocyclic	O
derivatives	O
of	O
[	O
dPen1	O
,	O
Gln4	O
,	O
Lys	O
(	O
CHO	O
)	O
8	O
]	O
oxytocin	O
were	O
antagonists	O
of	O
oxytocin	O
which	O
was	O
attributed	O
to	O
the	O
dPen1	O
substitution	O
.	O
The	O
corresponding	O
hydroxy	B-IUPAC
derivatives	B-MODIFIER
were	O
less	O
active	O
of	O
inactive	O
.	O
Such	O
type	O
II	O
(	O
covalent	O
)	O
mechanism	O
-	O
based	O
inactivation	O
is	O
supported	O
by	O
protein	O
labeling	O
with	O
8	O
-	O
[	O
3H	O
]	O
-	O
4	O
and	O
concomitant	O
release	O
of	O
bromide	O
and	O
fluoride	O
ions	O
.	O
Finally	O
,	O
from	O
series	O
II	O
,	O
we	O
have	O
obtained	O
a	O
weak	O
antagonist	O
in	O
the	O
F9	O
cellular	O
differentiation	O
assay	O
,	O
4	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
tert	I-IUPAC
-	I-IUPAC
butyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
propenyl	I-IUPAC
]	I-IUPAC
benzoic	I-IUPAC
acid	I-IUPAC
(	O
15	O
,	O
IC50	O
=	O
700	O
nM	O
)	O
.	O
In	O
general	O
,	O
the	O
in	O
vitro	O
tracheal	O
relaxant	O
action	O
and	O
positive	O
chronotropic	O
action	O
of	O
3	B-IUPAC
-	I-IUPAC
propylxanthines	I-IUPAC
were	O
increased	O
by	O
substitutions	O
with	O
nonpolar	O
functional	O
groups	O
at	O
the	O
1	O
-	O
position	O
,	O
but	O
decreased	O
by	O
any	O
substitution	O
at	O
the	O
7	O
-	O
position	O
.	O
gondii	O
,	O
rat	O
liver	O
,	O
Lactobacillus	O
casei	O
,	O
and	O
Escherichia	O
coli	O
,	O
and	O
selected	O
analogues	O
were	O
evaluated	O
as	O
inhibitors	O
of	O
the	O
growth	O
of	O
tumor	O
cells	O
in	O
culture	O
.	O
[	B-IUPAC
1,5	I-IUPAC
]	I-IUPAC
Benzodiazepines	I-IUPAC
,	O
e.g.	O
,	O
14	O
(	O
2,3	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrid	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
]	I-IUPAC
benzodiazepin	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
one	I-IUPAC
)	O
(	O
IC50	O
=	O
4.9	O
nM	O
,	O
Ed50	O
=	O
0.03	O
mg	O
/	O
kg	O
po	O
)	O
,	O
were	O
found	O
to	O
possess	O
equivalent	O
or	O
superior	O
potency	O
to	O
the	O
1,4	B-IUPAC
-	I-IUPAC
dihydropyridine	I-IUPAC
PAF	O
antagonist	O
UK	O
-	O
74,505	O
(	O
1,4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
ethoxycarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
pyrid	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
carbamoyl	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
)	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
A	O
structure	O
-	O
driven	O
approach	O
was	O
pursued	O
,	O
which	O
spanned	O
exploration	O
of	O
three	O
areas	O
:	O
(	O
1	O
)	O
5/6	O
fused	O
heterocycles	O
such	O
as	O
benzoxazole	O
,	O
benzothiophene	O
,	O
benzofuran	O
,	O
and	O
imidazopyridine	O
;	O
(	O
2	O
)	O
5	O
-	O
membered	O
heterocycles	O
,	O
including	O
oxadiazole	O
,	O
oxazole	O
,	O
thiazole	O
,	O
and	O
thiadiazole	O
,	O
with	O
pendant	O
aryl	O
groups	O
,	O
and	O
(	O
3	O
)	O
thioanilide	O
as	O
a	O
formal	O
equivalent	O
of	O
benzothiazole	O
.	O
The	O
prepared	O
compounds	O
are	O
heterocyclic	O
analogues	O
of	O
glutamic	O
acid	O
with	O
differing	O
chain	O
lengths	O
.	O
Each	O
of	O
these	O
molecules	O
satisfy	O
the	O
cannabinoid	O
pharmacophoric	O
requirements	O
,	O
i.e.	O
,	O
a	O
phenolic	O
oxygen	O
at	O
C1	O
and	O
a	O
side	O
chain	O
of	O
acceptable	O
length	O
at	O
C3	O
.	O
Their	O
structure	O
-	O
activity	O
relationships	O
(	O
SAR	O
)	O
for	O
inhibition	O
of	O
the	O
isolated	O
enzyme	O
more	O
closely	O
resemble	O
those	O
of	O
the	O
[	O
3,2	O
-	O
d	O
]	O
than	O
the	O
[	B-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridopyrimidine	I-IUPAC
isomers	O
.	O
All	O
these	O
peptides	O
were	O
also	O
tested	O
as	O
product	O
inhibitors	O
for	O
the	O
plasma	O
and	O
lung	O
converting	O
enzymes	O
.	O
Hydrazinolysis	O
of	O
compound	O
4	O
gave	O
1	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
p	I-IUPAC
-	I-IUPAC
(	I-IUPAC
carbomethoxy	I-IUPAC
)	I-IUPAC
thiophenoxy	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
butanone	I-IUPAC
oxime	I-IUPAC
(	O
5	O
)	O
,	O
which	O
was	O
used	O
for	O
the	O
construction	O
of	O
the	O
title	O
compound	O
2	O
by	O
modification	O
of	O
the	O
Boon	O
and	O
Leigh	O
procedure	O
.	O
Within	O
this	O
series	O
of	O
derivatives	O
,	O
2	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methylsemicarbazono	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
methylenedioxyphenylacetic	I-IUPAC
acid	I-IUPAC
methyl	I-IUPAC
ester	I-IUPAC
(	O
10	O
)	O
proved	O
to	O
be	O
the	O
most	O
active	O
compound	O
.	O
The	O
derivatives	O
18a	O
-	O
e	O
were	O
obtained	O
by	O
introducing	O
on	O
the	O
nitrogen	O
of	O
amine	O
4	O
the	O
n	B-IUPAC
-	I-IUPAC
propyl	I-IUPAC
and	O
2	B-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
or	O
3	B-IUPAC
-	I-IUPAC
phenylpropyl	I-IUPAC
groups	B-MODIFIER
which	O
can	O
be	O
accommodated	O
by	O
the	O
D	O
-	O
2	O
receptor	O
lipophilic	O
sites	O
3C	O
and	O
pi	O
3	O
,	O
respectively	O
.	O
B	O
reported	O
here	O
,	O
the	O
Ile3	O
analogue	O
of	O
A	O
,	O
is	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
]	O
AVT	O
(	O
5	O
below	O
)	O
and	O
C	O
is	O
our	O
previously	O
reported	O
potent	O
nonselective	O
oxytocin	O
antagonist	O
/	O
AVP	O
V1	O
antagonist	O
,	O
[	B-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
mercapto	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
,	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
pentamethylenepropionic	I-IUPAC
acid	I-IUPAC
)	I-IUPAC
,	I-IUPAC
2	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methyltyrosine	I-IUPAC
,	I-IUPAC
8	I-IUPAC
-	I-IUPAC
ornithine	I-IUPAC
]	I-IUPAC
vasotocin	I-IUPAC
(	O
d	O
(	O
CH2	O
)	O
5	O
[	O
Tyr	O
(	O
Me	O
)	O
2	O
]	O
OVT	O
)	O
.	O
Analogues	O
1-14	O
were	O
tested	O
for	O
agonistic	O
and	O
antagonistic	O
activities	O
by	O
antidiuretic	O
,	O
vasopressor	O
,	O
and	O
oxytocic	O
assays	O
in	O
rats	O
.	O
However	O
,	O
two	O
hydantoin	O
derivatives	O
,	O
5	O
and	O
8	O
,	O
were	O
totally	O
inactive	O
in	O
inhibiting	O
AlDH	O
in	O
vivo	O
.	O
Among	O
ArNH	O
(	O
CH2	O
)	O
n	O
compounds	O
with	O
n	O
=	O
1-3	O
and	O
either	O
2'	B-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
dimethoxyphenyl	I-IUPAC
or	O
3'	B-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxyphenyl	I-IUPAC
as	O
the	O
Ar	O
moiety	O
,	O
activity	O
decreased	O
in	O
the	O
order	O
n	O
=	O
1	O
&	O
gt	O
;	O
n	O
=	O
2	O
&	O
gt	O
;	O
n	O
=	O
3	O
.	O
The	O
compounds	O
initially	O
synthesized	O
for	O
this	O
study	O
were	O
(	B-PARTIUPAC
+	I-PARTIUPAC
/	I-PARTIUPAC
-	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
anti	I-PARTIUPAC
-	I-PARTIUPAC
and	O
syn	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
2a	I-IUPAC
,	I-IUPAC
3,4,5	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2H	I-IUPAC
-	I-IUPAC
naphtho	I-IUPAC
[	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
bc	I-IUPAC
]	I-IUPAC
furan	I-IUPAC
(	O
4a	O
,	O
b	O
)	O
,	O
respectively	O
,	O
and	O
their	O
8	O
-	O
bromo	O
derivatives	O
4c	O
,	O
d	O
,	O
respectively	O
.	O
The	O
phosphate	O
anion	O
,	O
derived	O
from	O
P	O
-	O
O	O
bond	O
cleavage	O
of	O
these	O
latter	O
compounds	O
,	O
is	O
only	O
observed	O
at	O
low	O
levels	O
after	O
a	O
long	O
period	O
of	O
hydrolysis	O
.	O
Improved	O
rationally	O
designed	O
lead	O
drug	O
structures	O
against	O
African	O
trypanosomiasis	O
,	O
Chagas	O
disease	O
,	O
and	O
leishmaniasis	O
were	O
obtained	O
against	O
trypanothione	O
reductase	O
from	O
Trypanosoma	O
cruzi	O
.	O
The	O
fact	O
that	O
the	O
naphthofurans	O
lack	O
LSD	O
-	O
like	O
activity	O
suggests	O
that	O
they	O
do	O
not	O
bind	O
to	O
the	O
serotonin	O
receptor	O
in	O
a	O
way	O
such	O
that	O
the	O
tricyclic	O
naphthofuran	O
nucleus	O
is	O
bioisosteric	O
with	O
,	O
and	O
directly	O
superimposable	O
upon	O
,	O
the	O
A	O
,	O
B	O
,	O
and	O
C	O
rings	O
of	O
LSD	O
.	O
The	O
reaction	O
of	O
6	B-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
azapurine	I-IUPAC
(	O
1	O
)	O
with	O
2,3,5	B-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
chloride	I-IUPAC
in	O
the	O
presence	O
of	O
Linde	O
AW	O
-	O
500	O
molecular	O
sieve	O
gave	O
a	O
2	O
:	O
1	O
mixture	O
of	O
2	O
and	O
3	O
,	O
respectively	O
.	O
Compounds	O
R	B-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
fluoromethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
THIQ	I-IUPAC
(	O
R	O
-	O
12	O
)	O
and	O
R	B-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
fluoromethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
aminosulfonyl	I-IUPAC
-	I-IUPAC
THIQ	I-IUPAC
(	O
R	O
-	O
13	O
)	O
and	O
both	O
enantiomers	O
of	O
3	B-IUPAC
-	I-IUPAC
chloromethyl	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
THIQ	I-IUPAC
(	O
R	O
-	O
and	O
S	O
-	O
30	O
)	O
are	O
the	O
most	O
selective	O
inhibitors	O
in	O
this	O
study	O
and	O
display	O
selectivities	O
(	O
alpha	O
(	O
2	O
)	O
-	O
adrenoceptor	O
K	O
(	O
i	O
)	O
/	O
PNMT	O
K	O
(	O
i	O
)	O
)	O
greater	O
than	O
200	O
.	O
Compound	O
32	O
was	O
100	O
-	O
fold	O
selective	O
for	O
CCK	O
(	O
2	O
)	O
over	O
CCK	O
(	O
1	O
)	O
receptors	O
based	O
on	O
the	O
affinity	O
estimate	O
obtained	O
in	O
a	O
guinea	O
pig	O
pancreas	O
radioligand	O
binding	O
assay	O
(	O
pK	O
(	O
i	O
)	O
=	O
5.0	O
)	O
.	O
Systematic	O
point	O
mutations	O
led	O
to	O
cyclo	O
[	O
21,29	O
]	O
[	O
D	O
-	O
Cys	O
(	O
21	O
)	O
Nle	O
(	O
23	O
)	O
Cys	O
(	O
29	O
)	O
]	O
-	O
uPA	O
(	O
21	O
)	O
(	O
-	O
)	O
(	O
30	O
)	O
,	O
which	O
still	O
binds	O
to	O
uPAR	O
but	O
is	O
resistant	O
to	O
proteolytic	O
cleavage	O
,	O
e.g.	O
,	O
by	O
the	O
tumor	O
-	O
associated	O
serine	O
proteases	O
uPA	O
and	O
plasmin	O
,	O
and	O
is	O
stable	O
in	O
blood	O
serum	O
or	O
plasma	O
.	O
(	B-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
Benzylpropylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorotetralin	I-IUPAC
(	O
10	O
)	O
behaved	O
as	O
an	O
inverse	O
agonist	O
at	O
both	O
DA	O
D2	O
and	O
D3	O
receptors	O
.	O
The	O
antidepressant	O
potential	O
of	O
the	O
lead	O
compounds	O
40	O
,	O
45	O
,	O
and	O
54	O
was	O
examined	O
by	O
means	O
of	O
the	O
forced	O
swimming	O
test	O
(	O
FST	O
)	O
in	O
rats	O
.	O
In	O
this	O
series	O
,	O
DA	O
agonist	O
activity	O
was	O
found	O
to	O
be	O
highly	O
dependent	O
on	O
the	O
size	O
of	O
the	O
N	B-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
substituent	B-MODIFIER
,	O
the	O
saturation	O
level	O
of	O
the	O
six	O
-	O
membered	O
ring	O
,	O
and	O
the	O
mode	O
of	O
attachment	O
of	O
the	O
2	B-IUPAC
-	I-IUPAC
aminothiazole	I-IUPAC
ring	B-MODIFIER
.	O
The	O
5	B-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
benzoyl	I-IUPAC
derivative	B-MODIFIER
,	O
10	O
,	O
displayed	O
Ki	O
values	O
of	O
680	O
and	O
273	O
nM	O
at	O
rat	O
A1	O
and	O
A2A	O
receptors	O
,	O
respectively	O
,	O
and	O
3.0	O
nM	O
at	O
human	O
A3	O
receptors	O
.	O
The	O
imidazole	O
ring	O
of	O
10	O
,	O
13	O
,	O
and	O
14	O
was	O
placed	O
'	O
upside	O
down	O
'	O
compared	O
with	O
1	O
,	O
making	O
the	O
interaction	O
of	O
the	O
N	O
(	O
pi	O
)	O
-	O
atom	O
with	O
Tyr431	O
possible	O
.	O
Further	O
,	O
the	O
predictive	O
ability	O
of	O
3D	O
QSAR	O
models	O
was	O
affirmed	O
by	O
predicting	O
the	O
activity	O
of	O
novel	O
2	B-IUPAC
-	I-IUPAC
naphthamidines	I-IUPAC
.	O
These	O
5,6	B-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
derivatives	B-MODIFIER
,	O
which	O
are	O
also	O
potential	O
prodrugs	O
to	O
3'	B-IUPAC
-	I-IUPAC
azido	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
deoxythymidine	I-IUPAC
(	O
AZT	O
)	O
,	O
were	O
designed	O
in	O
an	O
effort	O
to	O
enhance	O
the	O
duration	O
of	O
action	O
,	O
lipophilicity	O
,	O
and	O
cephalic	O
delivery	O
to	O
the	O
central	O
nervous	O
system	O
.	O
Cell	O
growth	O
inhibition	O
was	O
studied	O
with	O
two	O
L5178Y	O
murine	O
leukemia	O
cell	O
lines	O
,	O
parental	O
and	O
5	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
FdUrd	O
)	O
-	O
resistant	O
,	O
the	O
latter	O
70	O
-	O
fold	O
less	O
sensitive	O
toward	O
FdUrd	O
than	O
the	O
former	O
.	O
Authentic	O
(	O
2R	O
,	O
2	O
"	O
S	O
)	O
-	O
2	O
,	O
obtained	O
from	O
the	O
amide	O
formed	O
from	O
(	B-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthoxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxypropionic	I-IUPAC
acid	I-IUPAC
[	O
(	O
2S	O
)	O
-	O
5	O
]	O
and	O
(	B-IUPAC
2S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alaninol	I-IUPAC
by	O
diborane	O
reduction	O
,	O
facilitated	O
examination	O
of	O
stereochemical	O
aspects	O
of	O
this	O
process	O
.	O
3	B-IUPAC
-	I-IUPAC
(	I-IUPAC
Fluorosulfonyl	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
,	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
fluorosulfonyl	I-IUPAC
)	I-IUPAC
benzoyl	I-IUPAC
,	O
4	B-IUPAC
-	I-IUPAC
chlorobenzoyl	I-IUPAC
,	O
and	O
bromacetyl	B-IUPAC
derivatives	B-MODIFIER
of	O
two	O
parent	O
amines	O
,	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
hypoxanthine	I-IUPAC
and	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
aminobenzyl	I-IUPAC
)	I-IUPAC
hypoxanthine	I-IUPAC
,	O
were	O
synthesized	O
for	O
evaluation	O
in	O
this	O
connection	O
.	O
The	O
new	O
compounds	O
were	O
evaluated	O
for	O
their	O
affinity	O
at	O
the	O
dopamine	O
D1	O
and	O
D2	O
receptors	O
.	O
All	O
analogs	O
were	O
agonists	O
in	O
the	O
mouse	O
vas	O
deferens	O
(	O
MVD	O
)	O
and	O
guinea	O
pig	O
ileum	O
(	O
GPI	O
)	O
smooth	O
muscle	O
bioassays	O
,	O
displaying	O
MVD	O
and	O
GPI	O
potencies	O
consistent	O
with	O
their	O
delta	O
and	O
mu	O
opioid	O
receptor	O
affinities	O
,	O
respectively	O
.	O
A	O
similar	O
oxidation	O
of	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methyl	I-IUPAC
/	I-IUPAC
benzylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylpurine	I-IUPAC
(	O
12a	O
and	O
12b	O
)	O
and	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
methylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
purine	I-IUPAC
(	O
12c	O
)	O
with	O
MCPBA	O
gave	O
the	O
corresponding	O
sulfoxides	O
(	O
13a	O
-	O
c	O
)	O
,	O
which	O
on	O
further	O
oxidation	O
furnished	O
the	O
respective	O
sulfones	O
(	O
14a	O
-	O
c	O
)	O
.	O
Moreover	O
,	O
the	O
marked	O
effectiveness	O
of	O
the	O
angularly	O
-	O
cyclized	O
[	B-IUPAC
1,3	I-IUPAC
]	I-IUPAC
thiazino	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
i	I-IUPAC
]	I-IUPAC
purinones	I-IUPAC
,	O
which	O
constitute	O
an	O
interesting	O
new	O
class	O
of	O
inhibitors	O
,	O
together	O
with	O
the	O
weak	O
activity	O
of	O
linearly	O
-	O
cyclized	O
derivatives	O
,	O
allowed	O
us	O
to	O
characterize	O
more	O
precisely	O
the	O
lipophilic	O
region	O
of	O
the	O
enzyme	O
facing	O
the	O
N	O
(	O
1	O
)	O
-	O
C	O
(	O
2	O
)	O
positions	O
of	O
the	O
substrate	O
hypoxanthine	O
.	O
Low	O
-	O
energy	O
conformers	O
of	O
this	O
analog	O
could	O
only	O
be	O
effectively	O
superimposed	O
with	O
low	O
-	O
energy	O
conformers	O
of	O
the	O
parent	O
peptide	O
in	O
which	O
the	O
Phe3	O
side	O
chain	O
conformation	O
was	O
limited	O
to	O
chi	O
1	O
approximately	O
-	O
60	O
degrees	O
.	O
Many	O
of	O
these	O
5	B-IUPAC
-	I-IUPAC
thio	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridinecarboxylic	I-IUPAC
acid	I-IUPAC
derivatives	B-MODIFIER
were	O
orally	O
active	O
antihypertensive	O
agents	O
in	O
the	O
spontaneously	O
hypertensive	O
rat	O
.	O
Addition	O
of	O
aryllithium	O
or	O
aryl	O
Grignard	O
reagents	O
to	O
1a	O
,	O
b	O
and	O
formic	O
acid	O
reduction	O
afforded	O
cis	B-PARTIUPAC
-	I-PARTIUPAC
and	O
trans	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
arylspiro	I-IUPAC
[	I-IUPAC
cyclohexane	I-IUPAC
-	I-IUPAC
1,1	I-IUPAC
'	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
isobenzofurans	I-IUPAC
]	I-IUPAC
3a	O
-	O
f	O
,	O
which	O
were	O
converted	O
to	O
secondary	O
amine	O
analogues	O
5a	O
-	O
e	O
.	O
The	O
in	O
vivo	O
results	O
show	O
that	O
the	O
4	B-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
carbamate	I-IUPAC
8	O
and	O
the	O
4	B-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
carbamate	I-IUPAC
9	O
in	O
this	O
series	O
had	O
the	O
best	O
anti	O
-	O
PCP	O
activity	O
by	O
both	O
intravenous	O
and	O
oral	O
administration	O
at	O
a	O
dosage	O
level	O
of	O
22	O
mol	O
and	O
33	O
micromol	O
/	O
kg	O
/	O
day	O
,	O
respectively	O
.	O
Furthermore	O
,	O
the	O
involvement	O
of	O
the	O
4	B-PARTIUPAC
-	I-PARTIUPAC
aminobenzyl	I-PARTIUPAC
moiety	B-MODIFIER
in	O
the	O
anticonvulsant	O
activity	O
was	O
evaluated	O
by	O
testing	O
derivative	O
23	O
.	O
For	O
the	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	O
substituted	B-MODIFIER
benzo	B-IUPAC
[	I-IUPAC
h	I-IUPAC
]	I-IUPAC
chromen	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
,	O
a	O
morpholine	O
substituent	O
at	O
this	O
position	O
was	O
essential	O
for	O
activity	O
.	O
Upon	O
evaluation	O
of	O
these	O
final	O
nucleosides	O
,	O
the	O
5	B-IUPAC
-	I-IUPAC
fluorocytosine	I-IUPAC
derivative	B-MODIFIER
51	O
was	O
found	O
to	O
be	O
the	O
most	O
potent	O
compound	O
among	O
those	O
tested	O
.	O
The	O
adenosine	O
antagonist	O
9	B-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanyl	I-IUPAC
)	I-IUPAC
[	I-IUPAC
1,2,4	I-IUPAC
]	I-IUPAC
triazolo	I-IUPAC
[	I-IUPAC
1,5	I-IUPAC
-	I-IUPAC
c	I-IUPAC
]	I-IUPAC
quinazolin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
(	O
CGS15943	O
)	O
binds	O
to	O
human	O
A3	O
receptors	O
with	O
high	O
affinity	O
(	O
Ki	O
=	O
14	O
nM	O
)	O
,	O
while	O
it	O
lacks	O
affinity	O
at	O
rat	O
A3	O
receptors	O
.	O
These	O
investigations	O
prompted	O
the	O
synthesis	O
and	O
evaluation	O
of	O
additional	O
diazepine	O
derivatives	O
,	O
which	O
are	O
described	O
in	O
the	O
following	O
paper	O
.	O
A	O
series	O
of	O
substituted	B-MODIFIER
1,4	B-IUPAC
-	I-IUPAC
dihydronaphthoquinones	I-IUPAC
,	O
hydroindoloquinones	O
,	O
benzofuran	B-IUPAC
-	I-IUPAC
4,7	I-IUPAC
-	I-IUPAC
dihydroquinones	I-IUPAC
,	O
and	O
benzothiophene	B-IUPAC
-	I-IUPAC
4,7	I-IUPAC
-	I-IUPAC
dihydroquinones	I-IUPAC
were	O
synthesized	O
and	O
evaluated	O
for	O
inhibitory	O
activity	O
against	O
5	O
-	O
lipoxygenase	O
.	O
Stereospecific	O
glycosylation	O
was	O
achieved	O
by	O
the	O
use	O
of	O
2	B-PARTIUPAC
-	I-PARTIUPAC
O	I-PARTIUPAC
-	I-PARTIUPAC
acetyl	I-PARTIUPAC
-	I-PARTIUPAC
3,4,6	I-PARTIUPAC
-	I-PARTIUPAC
tri	I-PARTIUPAC
-	I-PARTIUPAC
O	I-PARTIUPAC
-	I-PARTIUPAC
benzylglucopyranosyl	I-PARTIUPAC
and	O
-	B-PARTIUPAC
mannopyranosyl	I-PARTIUPAC
trichloroacetimidates	I-PARTIUPAC
as	O
donors	O
,	O
with	O
trimethylsilyl	B-IUPAC
trifluoromethanesulfonate	I-IUPAC
as	O
catalyst	O
in	O
the	O
presence	O
of	O
molecular	O
sieves	O
at	O
-	O
78	O
degrees	O
C	O
.	O
Spiro	O
-	O
joining	O
of	O
the	O
phenyl	B-IUPAC
and	O
the	O
piperidine	B-IUPAC
rings	B-MODIFIER
into	O
a	O
spiro	B-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperdine	I-IUPAC
]	I-IUPAC
ring	B-MODIFIER
system	I-MODIFIER
resulted	O
in	O
even	O
more	O
selective	O
compounds	O
.	O
Z	O
-	O
Olefin	O
4b	O
and	O
2	B-IUPAC
-	I-IUPAC
aminoadenallene	I-IUPAC
(	O
5c	O
)	O
are	O
substrates	O
for	O
adenosine	O
deaminase	O
.	O
Each	O
compound	O
's	O
potential	O
for	O
preventive	O
and	O
therapeutic	O
activity	O
stems	O
from	O
the	O
compound	O
's	O
potential	O
to	O
block	O
viral	O
attachment	O
,	O
virus	O
-	O
cell	O
fusion	O
,	O
or	O
virus	O
entry	O
into	O
host	O
cells	O
or	O
to	O
counter	O
potential	O
mechanisms	O
of	O
HCV	O
immune	O
evasion	O
.	O
1	B-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
Ribofuranosyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxamide	I-IUPAC
was	O
obtained	O
by	O
deacetylation	O
of	O
the	O
corresponding	O
tri	B-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
acetyl	I-IUPAC
nucleoside	I-IUPAC
11	O
or	O
by	O
deacetylation	O
and	O
ammonolysis	O
of	O
the	O
blocked	O
ethyl	B-IUPAC
5	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
nucleoside	I-IUPAC
10	O
,	O
which	O
was	O
prepared	O
from	O
the	O
stannic	O
chloride	O
catalyzed	O
condensation	O
of	O
the	O
trimethylsilyl	B-IUPAC
derivative	B-MODIFIER
of	O
ethyl	B-IUPAC
4	I-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methylimidazole	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carboxylate	I-IUPAC
.	O
Hydrolysis	O
of	O
6	O
and	O
11	O
yielded	O
7	B-IUPAC
-	I-IUPAC
hydroxymethyl	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
7	O
)	O
and	O
5	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxymethyl	I-IUPAC
-	I-IUPAC
12	I-IUPAC
-	I-IUPAC
methylbenz	I-IUPAC
[	I-IUPAC
a	I-IUPAC
]	I-IUPAC
anthracene	I-IUPAC
(	O
12	O
)	O
,	O
respectively	O
.	O
This	O
orientation	O
can	O
explain	O
both	O
the	O
increased	O
relative	O
potency	O
and	O
the	O
maximum	O
effect	O
of	O
10	O
,	O
13	O
,	O
and	O
14	O
compared	O
with	O
1	O
.	O
1c	O
was	O
prepared	O
by	O
condensing	O
2	B-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
pivaloyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,3,2	I-IUPAC
-	I-IUPAC
dioxaphosphorinane	I-IUPAC
with	O
2'	B-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorouridine	I-IUPAC
(	O
FUdR	O
)	O
in	O
the	O
presence	O
of	O
triphenylphosphine	O
and	O
diethyl	O
azodicarboxylate	O
.	O
Tests	O
for	O
time	O
-	O
dependent	O
loss	O
of	O
enzyme	O
activity	O
(	O
inactivation	O
)	O
were	O
performed	O
under	O
conditions	O
in	O
which	O
a	O
large	O
proportion	O
of	O
each	O
phosphokinase	O
was	O
present	O
as	O
an	O
enzyme	O
-	O
inhibitor	O
complex	O
.	O
We	O
have	O
synthesized	O
five	O
fluorinated	O
derivatives	O
of	O
WAY	O
100635	O
,	O
N	B-IUPAC
-	I-IUPAC
{	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
piperazino	I-IUPAC
]	I-IUPAC
ethyl	I-IUPAC
}	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
)	I-IUPAC
cyclohe	I-IUPAC
xaneca	I-IUPAC
rboxamide	I-IUPAC
(	O
4a	O
)	O
,	O
using	O
various	O
acids	O
in	O
place	O
of	O
the	O
cyclohexanecarboxylic	B-IUPAC
acid	I-IUPAC
(	O
CHCA	O
,	O
2a	O
)	O
in	O
the	O
reaction	O
scheme	O
.	O
4	B-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
arylsulfonyl	I-IUPAC
)	I-IUPAC
furoxans	I-IUPAC
were	O
the	O
most	O
potent	O
derivatives	O
of	O
the	O
series	O
.	O
The	O
cytotoxicity	O
of	O
the	O
topoisomerase	O
II	O
inhibitor	O
etoposide	O
was	O
also	O
potentiated	O
.	O
Efforts	O
to	O
improve	O
the	O
antiallergic	O
potency	O
of	O
the	O
title	O
series	O
by	O
variation	O
of	O
the	O
indole	O
substituents	O
(	O
R1	O
,	O
R2	O
,	O
R	O
)	O
and	O
the	O
length	O
of	O
the	O
alkanoic	O
chain	O
(	O
n	O
=	O
1	O
,	O
2	O
,	O
3	O
)	O
led	O
to	O
the	O
selection	O
of	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
pyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
fluorobenzyl	I-IUPAC
)	I-IUPAC
indol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
acetamide	I-IUPAC
45	O
,	O
out	O
of	O
41	O
compounds	O
.	O
It	O
is	O
concluded	O
that	O
H2	O
-	O
receptor	O
antagonist	O
affinity	O
in	O
the	O
mifentidine	O
series	O
is	O
mostly	O
dependent	O
on	O
the	O
availability	O
of	O
the	O
neutral	O
species	O
.	O
v	O
.	O
Out	O
of	O
a	O
library	O
of	O
over	O
500	O
compounds	O
,	O
including	O
randomly	O
selected	O
small	O
molecules	O
and	O
rationally	O
designed	O
small	O
molecules	O
,	O
only	O
the	O
1	B-IUPAC
-	I-IUPAC
boraadamantaneamine	I-IUPAC
compounds	B-MODIFIER
and	O
structurally	O
similar	O
analogues	O
display	O
a	O
significant	O
antiproliferative	O
effect	O
on	O
the	O
CD81	O
-	O
enriched	O
astrocytes	O
relative	O
to	O
the	O
CD81	O
-	O
deficient	O
cell	O
lines	O
.	O
With	O
the	O
HL	O
-	O
60	O
assay	O
,	O
1a	O
and	O
1c	O
were	O
approximately	O
2	O
-	O
and	O
5	O
-	O
fold	O
less	O
active	O
,	O
respectively	O
,	O
than	O
trans	O
-	O
retinoic	O
acid	O
.	O
These	O
compounds	O
have	O
the	O
same	O
affinity	O
at	O
the	O
D	O
-	O
2	O
site	O
as	O
the	O
DA	O
agonist	O
N	B-IUPAC
-	I-IUPAC
n	I-IUPAC
-	I-IUPAC
propyl	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ethylamine	I-IUPAC
(	O
2a	O
)	O
and	O
are	O
about	O
20	O
times	O
more	O
selective	O
than	O
DA	O
for	O
this	O
binding	O
site	O
.	O
Conversion	O
of	O
(	O
+	O
)	O
-	O
1f	O
to	O
its	O
2'	B-IUPAC
-	I-IUPAC
desoxy	I-IUPAC
analogue	B-MODIFIER
(	O
+	O
)	O
-	O
2d	O
resulted	O
in	O
a	O
27.5	O
-	O
fold	O
loss	O
in	O
affinity	O
.	O
A	O
number	O
of	O
the	O
compounds	O
inhibited	O
cholesterol	O
and	O
free	O
fatty	O
acid	O
biosynthesis	O
from	O
[	O
1-14	O
C	O
]	O
acetate	O
in	O
rat	O
liver	O
slices	O
in	O
vitro	O
.	O
The	O
derived	O
D2A	O
receptor	O
model	O
can	O
accommodate	O
both	O
the	O
N	B-IUPAC
-	I-IUPAC
propyl	I-IUPAC
substituent	B-MODIFIER
of	O
2	O
and	O
the	O
C11	B-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
substituent	B-MODIFIER
of	O
11	O
[	O
(	B-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
ethylaporphine	I-IUPAC
]	O
.	O
By	O
contrast	O
,	O
2,3	B-IUPAC
-	I-IUPAC
dibromopropene	I-IUPAC
(	O
19	O
)	O
afforded	O
smoothly	O
(	B-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
and	O
(	B-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
dibromocyclopropane	I-IUPAC
carboxylic	I-IUPAC
esters	I-IUPAC
24	O
+	O
25	O
.	O
The	O
compounds	O
were	O
tested	O
in	O
vitro	O
together	O
with	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
bromomethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
(	O
ABPA	O
)	O
as	O
inhibitors	O
of	O
the	O
binding	O
of	O
radioactive	O
-	O
labeled	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
isoxazolepropionic	I-IUPAC
acid	I-IUPAC
(	O
AMPA	O
)	O
to	O
rat	O
brain	O
synaptic	O
membranes	O
.	O
The	O
lead	O
compound	O
of	O
a	O
new	O
series	O
of	O
3	B-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
ethers	I-IUPAC
,	O
the	O
azetidine	O
derivative	O
A	O
-	O
85380	O
(	O
3	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
azetidinylmethoxy	I-IUPAC
]	I-IUPAC
pyridine	I-IUPAC
)	O
,	O
is	O
a	O
potent	O
and	O
selective	O
ligand	O
for	O
the	O
human	O
alpha4beta2	O
nicotinic	O
acetylcholine	O
receptor	O
(	O
nAChR	O
)	O
subtype	O
.	O
The	O
N	B-MODIFIER
-	I-MODIFIER
6	I-MODIFIER
glycosylated	I-MODIFIER
imidazo	B-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isothiazoles	I-IUPAC
also	O
were	O
inactive	O
in	O
antiproliferative	O
and	O
cytotoxicity	O
assays	O
,	O
except	O
for	O
3	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosylimidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isothiazole	I-IUPAC
(	O
15a	O
)	O
and	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
benzylthio	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
ribofuranosyl	I-IUPAC
)	I-IUPAC
imidazo	I-IUPAC
[	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
isothiaz	I-IUPAC
ole	I-IUPAC
(	O
5e	O
)	O
,	O
which	O
showed	O
moderate	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
.	O
7	B-IUPAC
-	I-IUPAC
Aza	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
oxo	I-IUPAC
-	I-IUPAC
7,8	I-IUPAC
-	I-IUPAC
dihydroretinoids	I-IUPAC
(	O
12	O
,	O
13	O
)	O
were	O
synthesized	O
from	O
benzeneamines	O
and	O
the	O
acyl	B-IUPAC
cyano	I-IUPAC
or	O
bromo	B-IUPAC
derivative	B-MODIFIER
of	O
the	O
monomethyl	O
ester	O
of	O
3,7	B-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
2,4,6	I-IUPAC
-	I-IUPAC
octatriene	I-IUPAC
-	I-IUPAC
1,8	I-IUPAC
-	I-IUPAC
dioic	I-IUPAC
acid	I-IUPAC
.	O
It	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
both	O
cAMP	O
phosphodiesterase	O
and	O
platelet	O
aggregation	O
.	O
Aromatic	O
substitution	O
patterns	O
were	O
varied	O
with	O
the	O
goal	O
of	O
identifying	O
a	O
compound	O
having	O
affinities	O
for	O
the	O
D	O
(	O
2	O
)	O
and	O
D	O
(	O
4	O
)	O
receptors	O
in	O
a	O
ratio	O
similar	O
to	O
that	O
observed	O
for	O
the	O
atypical	O
neuroleptic	O
clozapine	O
.	O
carinii	O
DHFR	O
,	O
0.57	O
nM	O
against	O
M	O
.	O
In	O
contrast	O
,	O
the	O
(	B-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
substituent	B-MODIFIER
on	O
the	O
piperidine	O
ring	O
conferred	O
a	O
much	O
larger	O
set	O
of	O
minimum	O
-	O
energy	O
conformations	O
on	O
II	O
.	O
Compounds	O
5	O
and	O
6	O
also	O
demonstrated	O
modest	O
anti	O
-	O
hepatitis	O
B	O
virus	O
activity	O
against	O
DHBV	O
(	O
EC	O
(	O
50	O
)	O
=	O
19.9-23.6	O
microM	O
)	O
.	O
These	O
compounds	O
were	O
designed	O
to	O
improve	O
the	O
cell	O
penetration	O
of	O
a	O
previously	O
reported	O
series	O
of	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	O
substituted	B-MODIFIER
-	O
pyrido	B-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidines	I-IUPAC
which	O
had	O
shown	O
significant	O
potency	O
and	O
remarkable	O
selectivity	O
for	O
Toxoplasma	O
gondii	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
,	O
but	O
had	O
much	O
lower	O
inhibitory	O
effects	O
on	O
the	O
growth	O
of	O
T	O
.	O
Replacing	O
the	O
A1	O
side	O
chain	O
of	O
this	O
derivative	O
with	O
a	O
tert	B-IUPAC
-	I-IUPAC
butyl	I-IUPAC
group	B-MODIFIER
and	O
replacing	O
the	O
X	O
position	O
with	O
glutamine	O
led	O
to	O
a	O
derivative	O
with	O
an	O
IC50	O
of	O
2.8	O
nM	O
and	O
an	O
EC50	O
of	O
0.19	O
microM	O
,	O
a	O
26	O
-	O
fold	O
improvement	O
over	O
(	B-IUPAC
S	I-IUPAC
*	I-IUPAC
,	I-IUPAC
R	I-IUPAC
*	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
mercaptopropyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
valyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
isoquinolinyl	I-IUPAC
]	I-IUPAC
carbonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
methionine	I-IUPAC
.	O
Substitution	O
of	O
the	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethoxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
group	B-MODIFIER
by	O
ethyl	B-IUPAC
,	O
butyl	B-IUPAC
,	O
methoxymethyl	B-IUPAC
,	O
(	B-IUPAC
propyloxy	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
,	O
and	O
(	B-IUPAC
butyloxy	I-IUPAC
)	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
groups	B-MODIFIER
somewhat	O
improved	O
the	O
original	O
anti	O
-	O
HIV	O
-	O
1	O
activity	O
of	O
HEPT	O
.	O
A	O
complete	O
[	O
i	O
-	O
(	O
i	O
+	O
3	O
)	O
]	O
scan	O
of	O
cyclo	O
(	O
i	O
,	O
i	O
+	O
3	O
)	O
[	O
MeTyr1	O
,	O
Ala15	O
,	O
Glui	O
,	O
Lys	O
(	O
i	O
+	O
3	O
)	O
,	O
Nle27	O
]	O
-	O
hGHRH	O
(	O
1-29	O
)	O
-	O
NH2	O
was	O
then	O
produced	O
in	O
order	O
to	O
test	O
the	O
effects	O
of	O
a	O
Glu	O
-	O
to	O
-	O
Lys	O
lactam	O
bridge	O
at	O
all	O
points	O
in	O
the	O
peptide	O
.	O
We	O
have	O
further	O
modified	O
the	O
flavone	O
structure	O
to	O
achieve	O
a	O
degree	O
of	O
selectivity	O
for	O
cloned	O
human	O
brain	O
A3	O
receptors	O
,	O
determined	O
in	O
competitive	O
binding	O
assays	O
versus	O
[	O
125I	O
]	O
AB	O
-	O
MECA	O
[	O
N6	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
iodobenzyl	I-IUPAC
)	I-IUPAC
adenosine	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylur	I-IUPAC
onamide	I-IUPAC
)	I-IUPAC
]	O
.	O
N	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
omega	I-PARTIUPAC
-	I-PARTIUPAC
Aminoalkyl	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
2,2,5,5	I-PARTIUPAC
-	I-PARTIUPAC
tetramethyl	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
pyrroline	I-PARTIUPAC
-	I-PARTIUPAC
or	O
-	B-PARTIUPAC
pyrrolidine	I-PARTIUPAC
-	I-PARTIUPAC
3	I-PARTIUPAC
-	I-PARTIUPAC
carboxamides	I-PARTIUPAC
were	O
acylated	O
on	O
the	O
primary	O
amino	O
group	O
of	O
the	O
side	O
chain	O
by	O
means	O
of	O
reactive	O
acid	O
derivatives	O
(	O
acid	O
chlorides	O
,	O
activated	O
esters	O
,	O
phthalic	O
anhydrides	O
,	O
phthalimide	O
,	O
2	B-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
4H	I-IUPAC
-	I-IUPAC
3,1	I-IUPAC
-	I-IUPAC
benzoxazin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
)	O
or	O
they	O
were	O
alkylated	O
by	O
forming	O
the	O
Schiff	O
bases	O
and	O
subsequent	O
sodium	O
borohydride	O
reduction	O
.	O
Analysis	O
of	O
the	O
SAR	O
established	O
for	O
previous	O
papers	O
in	O
this	O
series	O
prompted	O
the	O
design	O
and	O
synthesis	O
of	O
(	B-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
benzyloxyphenyl	I-IUPAC
)	I-IUPAC
pent	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
enoic	I-IUPAC
acid	I-IUPAC
3	O
which	O
was	O
found	O
to	O
be	O
a	O
moderately	O
active	O
inhibitor	O
of	O
the	O
binding	O
of	O
[	O
125I	O
]	O
ET	O
-	O
1	O
to	O
ETA	O
receptors	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O
The	O
mechanism	O
of	O
anticonvulsant	O
action	O
of	O
these	O
agents	O
is	O
not	O
clear	O
although	O
it	O
appears	O
that	O
interaction	O
at	O
the	O
[	O
3H	O
]	O
1	O
sites	O
may	O
be	O
involved	O
.	O
Hydroxymethyl	O
compound	O
14	O
was	O
obtained	O
by	O
deamination	O
of	O
reported	O
2,4	B-IUPAC
-	I-IUPAC
diaminopyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
methanol	I-IUPAC
(	O
12a	O
)	O
in	O
refluxing	O
1	O
N	O
NaOH	O
.	O
Similarly	O
,	O
intraperitoneal	O
administration	O
of	O
(	O
FMS	O
)	O
(	O
3	O
)	O
-	O
insulin	O
to	O
healthy	O
rats	O
had	O
a	O
prolonged	O
glucose	O
-	O
lowering	O
effect	O
.	O
At	O
6	O
h	O
postinjection	O
of	O
[	O
131I	O
]	O
MIH	O
-	O
NGA	O
,	O
80%	O
of	O
the	O
injected	O
radioactivity	O
was	O
recovered	O
in	O
the	O
urine	O
.	O
Our	O
results	O
highlight	O
the	O
importance	O
of	O
the	O
doubly	O
negative	O
charge	O
borne	O
by	O
the	O
pY	O
+	O
1	O
amino	O
acid	O
in	O
accordance	O
with	O
the	O
interactions	O
observed	O
in	O
the	O
complex	O
crystallized	O
between	O
mAZ	O
-	O
pTyr	O
-	O
(	O
alphaMe	O
)	O
pTyr	O
-	O
Asn	O
-	O
NH2	O
and	O
the	O
Grb2	O
SH2	O
domain	O
.	O
The	O
N	O
-	O
methyl	O
analogue	O
2	O
and	O
N	O
-	O
formyl	O
analogue	O
3	O
were	O
prepared	O
from	O
11	O
and	O
1	O
,	O
respectively	O
.	O
A	O
number	O
of	O
such	O
compounds	O
were	O
synthesized	O
,	O
including	O
S	B-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
aminopropylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxypropyl	I-IUPAC
dihydrogen	I-IUPAC
phosphorothioate	I-IUPAC
(	O
11	O
,	O
n	O
equals	O
3	O
)	O
,	O
S	B-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxypropylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
dihydrogen	I-IUPAC
phosphorothioate	I-IUPAC
(	O
20	O
)	O
and	O
its	O
propyl	B-IUPAC
homolog	B-MODIFIER
26	O
,	O
N	B-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxytrimethylene	I-IUPAC
)	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
S	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
dihydrogen	I-IUPAC
phosphorothioate	I-IUPAC
)	I-IUPAC
(	O
40	O
)	O
,	O
S	B-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
hydroxyethylamino	I-IUPAC
)	I-IUPAC
propylaminoi1ethyl	I-IUPAC
dihydrogen	I-IUPAC
phosphorothioate	I-IUPAC
(	O
44	O
)	O
,	O
and	O
sodium	B-IUPAC
S	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypropyl	I-IUPAC
hydrogen	I-IUPAC
phosphorothioate	I-IUPAC
(	O
49	O
)	O
.	O
Finally	O
,	O
the	O
iron	O
-	O
clearing	O
efficiency	O
of	O
the	O
(	O
S	O
)	O
-	O
4'	O
-	O
(	O
HO	O
)	O
-	O
DADFT	O
conjugates	O
was	O
determined	O
in	O
a	O
bile	O
-	O
duct	O
-	O
cannulated	O
rodent	O
model	O
.	O
A	O
trend	O
which	O
suggested	O
that	O
more	O
lipophilic	O
transposed	O
amides	O
were	O
needed	O
to	O
increase	O
oral	O
activity	O
was	O
exploited	O
with	O
some	O
success	O
and	O
has	O
led	O
to	O
the	O
discovery	O
of	O
5q	O
(	O
4	B-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ethylbutyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
carbamoyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
ethylindol	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
]	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxy	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methylphenyl	I-IUPAC
)	I-IUPAC
sulfonyl	I-IUPAC
]	I-IUPAC
benzamide	I-IUPAC
)	O
,	O
a	O
transposed	O
amide	O
with	O
subnanomolar	O
affinity	O
for	O
the	O
leukotriene	O
receptor	O
and	O
an	O
oral	O
ED50	O
of	O
5	O
mg	O
/	O
kg	O
in	O
a	O
model	O
of	O
asthma	O
in	O
guinea	O
pigs	O
.	O
The	O
selectivity	O
of	O
9	O
as	O
a	O
glial	O
GABA	O
uptake	O
inhibitor	O
was	O
largely	O
lost	O
by	O
replacing	O
the	O
N	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
group	B-MODIFIER
of	O
9	O
by	O
an	O
ethyl	B-IUPAC
group	B-MODIFIER
,	O
compound	O
10	O
being	O
an	O
almost	O
equipotent	O
inhibitor	O
of	O
glial	O
(	O
IC	O
(	O
50	O
)	O
=	O
280	O
microM	O
)	O
and	O
neuronal	O
(	O
IC	O
(	O
50	O
)	O
=	O
400	O
microM	O
)	O
GABA	O
uptake	O
.	O
Silylation	O
of	O
1	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
xanthines	B-IUPAC
followed	O
by	O
alkylation	O
at	O
the	O
7	O
-	O
position	O
provides	O
a	O
facile	O
route	O
to	O
paraxanthine	O
analogs	O
.	O
These	O
chlorins	O
on	O
reacting	O
with	O
osmium	O
tetraoxide	O
produced	O
the	O
corresponding	O
vic	O
-	O
dihydroxybacteriochlorins	O
.	O
Optimization	O
of	O
structural	O
parameters	O
for	O
this	O
activity	O
yielded	O
compounds	O
54	O
,	O
55	O
,	O
34	O
,	O
65	O
,	O
and	O
22	O
,	O
which	O
were	O
selected	O
for	O
further	O
study	O
in	O
the	O
renal	O
hypertensive	O
dog	O
(	O
RHD	O
)	O
.	O
5	B-IUPAC
-	I-IUPAC
Pentyl	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
phenylhydantoin	I-IUPAC
(	O
8	O
)	O
,	O
the	O
most	O
potent	O
binder	O
to	O
the	O
sodium	O
channel	O
in	O
this	O
study	O
,	O
had	O
the	O
same	O
affinity	O
as	O
DPH	O
(	O
IC50	O
=	O
40	O
microM	O
)	O
,	O
revealing	O
that	O
one	O
phenyl	O
ring	O
is	O
sufficient	O
for	O
good	O
interactions	O
.	O
While	O
acetylation	O
of	O
the	O
N	O
-	O
terminus	O
of	O
16	O
(	O
i.e.	O
,	O
18	O
)	O
or	O
of	O
[	O
CalphaMe	O
-	O
Leu27	O
]	O
astressin	O
(	O
i.e.	O
,	O
19	O
)	O
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
in	O
vitro	O
potency	O
,	O
elongation	O
of	O
the	O
N	O
-	O
terminus	O
by	O
one	O
or	O
three	O
residues	O
in	O
addition	O
to	O
acetylation	O
resulted	O
in	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
CalphaMe	O
-	O
Leu27	O
,	O
Glu3	O
0	O
,	O
DHis32	O
,	O
Lys33	O
,	O
Nle38	O
]	O
Ac	O
-	O
hCRF	O
(	O
11-41	O
)	O
(	O
21	O
)	O
,	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
CalphaMe	O
-	O
Leu27	O
,	O
Glu30	O
,	O
Lys33	O
,	O
Nle38	O
]	O
Ac	O
-	O
hCRF	O
(	O
9-41	O
)	O
(	O
22	O
)	O
,	O
and	O
cyclo	O
(	O
30-33	O
)	O
[	O
DPhe12	O
,	O
Nle21	O
,	O
CalphaMe	O
-	O
Leu27	O
,	O
Glu30	O
,	O
DHis32	O
,	O
Lys33	O
,	O
Nle38	O
]	O
Ac	O
-	O
hCRF	O
(	O
9-41	O
)	O
(	O
23	O
)	O
that	O
were	O
longer	O
-	O
acting	O
than	O
6	O
and	O
8	O
(	O
ca.	O
2	O
h	O
inhibition	O
of	O
ACTH	O
secretion	O
at	O
25	O
micrograms	O
/	O
adrenalectomized	O
rat	O
)	O
.	O
N	O
-	O
Methylacetazolamide	O
was	O
shown	O
to	O
be	O
active	O
topically	O
in	O
reducing	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
to	O
a	O
small	O
but	O
statistically	O
significant	O
level	O
in	O
the	O
normotensive	O
rabbit	O
eye	O
.	O
This	O
hypothesis	O
can	O
be	O
tested	O
by	O
using	O
two	O
photoaffinity	O
probes	O
that	O
differ	O
only	O
in	O
the	O
N	O
-	O
unsubstituted	O
imine	O
vs	O
negatively	O
charged	O
(	O
delta	O
(	O
-	O
)	O
)	O
tip	O
.	O
Those	O
compounds	O
,	O
structurally	O
related	O
to	O
previously	O
described	O
potassium	O
channel	O
openers	O
such	O
as	O
the	O
benzothiadiazine	O
dioxide	O
BPDZ	O
73	O
,	O
were	O
tested	O
as	O
putative	O
K	O
(	O
ATP	O
)	O
channel	O
activators	O
on	O
the	O
pancreatic	O
endocrine	O
tissue	O
and	O
on	O
the	O
vascular	O
smooth	O
muscle	O
tissue	O
.	O
Further	O
evaluation	O
of	O
the	O
growth	O
inhibitory	O
activity	O
of	O
3	O
against	O
the	O
MTX	O
-	O
resistant	O
subline	O
of	O
CCRF	O
-	O
CEM	O
cells	O
(	O
R30dm	O
)	O
with	O
decreased	O
FPGS	O
indicated	O
that	O
poly	O
-	O
gamma	O
-	O
glutamylation	O
was	O
important	O
for	O
its	O
action	O
.	O
DPEAP	O
(	O
2	O
)	O
,	O
a	O
pyrrolo	B-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
amine	I-IUPAC
substituted	O
at	O
the	O
amino	O
group	O
(	O
N	O
(	O
4	O
)	O
)	O
,	O
was	O
found	O
to	O
exhibit	O
high	O
affinity	O
for	O
human	O
A	O
(	O
3	O
)	O
ARs	O
(	O
K	O
(	O
i	O
)	O
=	O
28	O
nM	O
)	O
,	O
whereas	O
N	O
(	O
4	O
)	O
-	O
unsubstituted	O
analogues	O
were	O
inactive	O
.	O
All	O
compounds	O
tested	O
,	O
except	O
for	O
13	O
and	O
14	O
,	O
exhibited	O
high	O
affinity	O
(	O
Ki	O
=	O
0.035-0.22	O
mM	O
range	O
relative	O
to	O
deoxyuridine	O
,	O
Ki	O
=	O
0.125	O
)	O
for	O
the	O
murine	O
NBMPR	O
-	O
sensitive	O
erythrocyte	O
nucleoside	O
transport	O
system	O
,	O
suggesting	O
that	O
these	O
iodohydrins	O
are	O
good	O
permeants	O
of	O
cell	O
membranes	O
.	O
Modeling	O
of	O
ligand	O
-	O
receptor	O
binding	O
site	O
interactions	O
yielded	O
an	O
interaction	O
site	O
model	O
for	O
the	O
5	O
-	O
HT1A	O
receptor	O
that	O
describes	O
a	O
gradual	O
change	O
in	O
binding	O
mode	O
for	O
C11	B-PARTIUPAC
-	I-PARTIUPAC
hydroxy	I-PARTIUPAC
,	O
-	B-PARTIUPAC
methoxy	I-PARTIUPAC
-	I-PARTIUPAC
,	O
and	O
-	B-PARTIUPAC
phenyl	I-PARTIUPAC
-	O
substituted	B-MODIFIER
derivatives	I-MODIFIER
.	O
8	B-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
Dimethylthiocarbamoyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
derivatives	B-MODIFIER
(	O
6a	O
-	O
e	O
)	O
rearranged	O
to	O
8	B-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylcarbamoyl	I-IUPAC
)	I-IUPAC
thio	I-IUPAC
derivatives	B-MODIFIER
(	O
7a	O
-	O
e	O
)	O
in	O
good	O
yields	O
.	O
Thus	O
,	O
4	B-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
estradiol	I-IUPAC
1	O
exhibited	O
similar	O
estrogen	O
receptor	O
affinity	O
as	O
the	O
catechol	O
estrogen	O
,	O
4	B-IUPAC
-	I-IUPAC
hydroxyestradiol	I-IUPAC
,	O
and	O
may	O
prove	O
useful	O
in	O
the	O
examination	O
of	O
the	O
biological	O
effects	O
of	O
4	B-IUPAC
-	I-IUPAC
hydroxyestrogens	I-IUPAC
.	O
Their	O
antiantidiuretic	O
pA2	O
values	O
are	O
as	O
follows	O
:	O
1	O
,	O
8.24	O
+	O
/	O
-	O
0.08	O
;	O
2	O
,	O
7.96	O
+	O
/	O
-	O
0.07	O
;	O
3	O
,	O
7.62	O
+	O
/	O
-	O
0.09	O
;	O
4	O
,	O
7.52	O
+	O
/	O
-	O
0.03	O
;	O
5	O
,	O
7.21	O
+	O
/	O
-	O
0.07	O
;	O
6	O
,	O
7.22	O
+	O
/	O
-	O
0.12	O
;	O
7	O
,	O
7.19	O
+	O
/	O
-	O
0.08	O
;	O
8	O
,	O
7.12	O
+	O
/	O
-	O
0.09	O
;	O
9	O
,	O
6.99	O
+	O
/	O
-	O
0.06	O
;	O
10	O
,	O
6.07	O
+	O
/	O
-	O
0.11	O
;	O
11	O
,	O
6.07	O
+	O
/	O
-	O
0.11	O
;	O
12	O
,	O
5.85	O
+	O
/	O
-	O
0.05	O
;	O
13	O
,	O
approximately	O
5.57	O
;	O
14	O
,	O
a	O
weak	O
agonist	O
(	O
0.004	O
U	O
/	O
mg	O
)	O
.	O
Several	O
derivatives	O
of	O
4,5	B-MODIFIER
-	I-MODIFIER
disubstituted	I-MODIFIER
imidazole	B-IUPAC
,	O
2,4,5	B-MODIFIER
-	I-MODIFIER
trisubstituted	I-MODIFIER
pyrimidine	B-IUPAC
,	O
2	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
purine	B-IUPAC
,	O
thiazolo	B-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
,	O
[	B-IUPAC
1,3	I-IUPAC
]	I-IUPAC
thiazino	I-IUPAC
[	I-IUPAC
3,2	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
,	O
thiazolo	B-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
i	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
,	O
[	B-IUPAC
1,3	I-IUPAC
]	I-IUPAC
thiazino	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
i	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
,	O
and	O
6	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
pyrazolo	B-IUPAC
[	I-IUPAC
3,4	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
were	O
synthesized	O
and	O
tested	O
as	O
inhibitors	O
of	O
the	O
xanthine	O
oxidase	O
enzyme	O
.	O
The	O
co	O
-	O
injection	O
of	O
PBR	O
-	O
selective	O
2	O
reduced	O
the	O
[	O
(	O
11	O
)	O
C	O
]	O
ligand	O
binding	O
in	O
the	O
two	O
regions	O
,	O
suggesting	O
that	O
binding	O
in	O
the	O
rat	O
brain	O
was	O
specific	O
to	O
PBR	O
.	O
Accordingly	O
,	O
antitumor	O
agents	O
can	O
be	O
made	O
selective	O
for	O
tumors	O
by	O
virtue	O
of	O
high	O
activity	O
under	O
hypoxic	O
conditions	O
.	O
Compounds	O
3-6	O
were	O
deblocked	O
with	O
chlorotrimethylsilane	B-IUPAC
and	O
sodium	O
iodide	O
in	O
acetonitrile	O
to	O
the	O
corresponding	O
5	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
)	I-IUPAC
vinyl	I-IUPAC
]	I-IUPAC
uracils	I-IUPAC
(	O
7-10	O
)	O
,	O
which	O
on	O
treatment	O
with	O
potassium	O
hydroxide	O
in	O
dioxane	O
yielded	O
the	O
corresponding	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
acylethynyl	I-IUPAC
)	I-IUPAC
uracils	I-IUPAC
(	O
11-14	O
)	O
.	O
Compounds	O
1-3	O
inhibited	O
growth	O
of	O
Detroit	O
98	O
and	O
L	O
cells	O
in	O
cell	O
culture	O
,	O
with	O
IC50s	O
ranging	O
from	O
2	O
to	O
0.018	O
microM	O
.	O
The	O
same	O
reactions	O
with	O
the	O
alpha	O
-	O
keto	O
sugar	O
gave	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
C	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
thymine	I-IUPAC
and	O
its	O
beta	O
-	O
anomer	O
.	O
casei	O
and	O
were	O
of	O
low	O
activity	O
(	O
IC50	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
.	O
All	O
the	O
peptides	O
have	O
similar	O
sets	O
of	O
low	O
-	O
energy	O
conformations	O
of	O
their	O
common	O
flexible	O
elements	O
,	O
the	O
Phe3	O
side	O
chain	O
and	O
the	O
peptide	O
group	O
between	O
the	O
first	O
residue	O
and	O
the	O
rigid	O
tripeptide	O
cycle	O
.	O
In	O
contrast	O
,	O
2	B-IUPAC
-	I-IUPAC
ethyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxypyridin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
,	O
which	O
is	O
not	O
metabolized	O
to	O
the	O
corresponding	O
(	O
carboxyalkyl	O
)	O
hydroxypyridinone	O
,	O
was	O
found	O
to	O
be	O
superior	O
to	O
Deferiprone	O
and	O
therefore	O
deserves	O
further	O
consideration	O
as	O
an	O
orally	O
active	O
iron	O
chelator	O
with	O
potential	O
for	O
the	O
treatment	O
of	O
iron	O
overload	O
associated	O
with	O
transfusion	O
-	O
dependent	O
thalassemia	O
.	O
The	O
synthesis	O
and	O
pharmacological	O
profile	O
of	O
a	O
series	O
of	O
neuroprotective	O
adenosine	O
agonists	O
are	O
described	O
.	O
Selective	O
protection	O
of	O
(	B-IUPAC
9R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
deoxoerythromycin	I-IUPAC
A	I-IUPAC
allowed	O
for	O
elimination	O
of	O
the	O
12	B-PARTIUPAC
-	I-PARTIUPAC
hydroxyl	I-PARTIUPAC
group	B-MODIFIER
to	O
afford	O
a	O
versatile	O
12,21	O
-	O
olefin	O
intermediate	O
.	O
Another	O
route	O
using	O
Grewe	O
cyclization	O
was	O
also	O
examined	O
for	O
the	O
synthesis	O
of	O
3	O
.	O
)	O
indicated	O
that	O
the	O
epoxyalkyl	O
group	O
on	O
the	O
phenolic	O
oxygen	O
had	O
an	O
optimal	O
length	O
of	O
four	O
carbons	O
with	O
respect	O
to	O
the	O
turnover	O
ratio	O
(	O
the	O
ratio	O
of	O
molecules	O
undergoing	O
turnover	O
compared	O
to	O
those	O
that	O
inactivate	O
the	O
enzyme	O
)	O
for	O
chymotrypsin	O
.	O
A	O
residual	O
enzymatic	O
activity	O
at	O
an	O
infinite	O
inhibitor	O
concentration	O
and	O
thus	O
a	O
catalytically	O
active	O
ternary	O
enzyme	O
-	O
substrate	O
-	O
inhibitor	O
complex	O
was	O
concluded	O
.	O
The	O
TS	O
inhibition	O
of	O
the	O
analogues	O
1b	O
-	O
g	O
was	O
estimated	O
by	O
calculating	O
the	O
inverse	O
relative	O
potency	O
,	O
defined	O
as	O
the	O
ratio	O
IC50	O
(	O
compound	O
)	O
/	O
IC50	O
(	O
1a	O
)	O
.	O
These	O
results	O
suggest	O
that	O
the	O
binding	O
of	O
hydantoins	O
to	O
the	O
sodium	O
channel	O
may	O
be	O
enhanced	O
by	O
(	O
a	O
)	O
a	O
free	O
imide	O
NH	O
group	O
and	O
(	O
b	O
)	O
an	O
increased	O
log	O
P	O
.	O
Among	O
the	O
pteridines	O
,	O
the	O
most	O
potent	O
against	O
P	O
.	O
The	O
aldehydes	O
were	O
converted	O
to	O
the	O
cyanohydrin	B-IUPAC
trimethylsilyl	I-IUPAC
ethers	I-IUPAC
,	O
which	O
,	O
in	O
turn	O
,	O
were	O
reduced	O
to	O
the	O
dimethoxyphenethanolamines	B-IUPAC
.	O
Thus	O
,	O
hydrophobicity	O
of	O
the	O
para	O
substituent	O
alone	O
cannot	O
account	O
for	O
the	O
dramatic	O
enhancement	O
of	O
hallucinogenic	O
activity	O
.	O
A	O
second	O
in	O
vivo	O
model	O
used	O
to	O
evaluate	O
PAF	O
antagonists	O
determines	O
the	O
ability	O
of	O
test	O
compounds	O
to	O
decrease	O
the	O
area	O
of	O
skin	O
wheals	O
induced	O
by	O
an	O
intradermal	O
injection	O
of	O
PAF	O
.	O
(	B-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
8	I-IUPAC
-	I-IUPAC
Aza	I-IUPAC
-	I-IUPAC
7	I-IUPAC
,	I-IUPAC
9	I-IUPAC
-	I-IUPAC
dioxospiro	I-IUPAC
[	I-IUPAC
4.5	I-IUPAC
]	I-IUPAC
decan	I-IUPAC
-	I-IUPAC
8	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
butyl	I-IUPAC
]	I-IUPAC
propylamino	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorote	I-IUPAC
tralin	I-IUPAC
(	O
18	O
)	O
bound	O
with	O
very	O
high	O
affinity	O
to	O
both	O
DA	O
D3	O
and	O
5	O
-	O
HT1A	O
receptors	O
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
and	O
was	O
also	O
characterized	O
as	O
a	O
dopaminergic	O
antagonist	O
.	O
Net	O
Pu	O
removal	O
[	O
Pu	O
excretion	O
(	O
treated	O
)	O
-	O
PU	O
excretion	O
(	O
control	O
)	O
]	O
,	O
expressed	O
as	O
percent	O
of	O
injected	O
Pu	O
,	O
was	O
as	O
follows	O
:	O
Na	O
salts	O
and	O
Zn	O
(	O
II	O
)	O
complexes	O
,	O
respectively	O
,	O
of	O
3	O
-	O
LIHOPO	O
(	O
54	O
,	O
56	O
)	O
,	O
3,4	O
-	O
LIHOPO	O
(	O
58	O
,	O
60	O
)	O
,	O
3,4,3	O
-	O
LIHOPO	O
(	O
73	O
,	O
76	O
)	O
;	O
Na	O
salts	O
of	O
MEHOPO	O
(	O
46	O
)	O
,	O
DFO	O
-	O
HOPO	O
(	O
78	O
)	O
;	O
Fe	O
(	O
III	O
)	O
complex	O
of	O
3,4,3	O
-	O
LIHOPO	O
(	O
79	O
)	O
.	O
Attempts	O
to	O
obtain	O
crystals	O
of	O
a	O
single	O
stereoisomer	O
failed	O
in	O
different	O
solvents	O
,	O
while	O
methanol	O
crystallization	O
of	O
the	O
product	O
obtained	O
from	O
(	B-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
tetrahydrofuran	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
ylmethyl	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
methylene	I-IUPAC
]	I-IUPAC
acetoacetate	I-IUPAC
and	O
methyl	B-IUPAC
3	I-IUPAC
-	I-IUPAC
aminocrotonate	I-IUPAC
yielded	O
good	O
-	O
quality	O
crystals	O
of	O
the	O
most	O
insoluble	O
racemate	O
which	O
proved	O
to	O
be	O
a	O
mixture	O
of	O
the	O
(	O
SS	O
)	O
/	O
(	O
RR	O
)	O
enantiomers	O
by	O
X	O
-	O
ray	O
crystallography	O
.	O
It	O
was	O
anticipated	O
that	O
1c	O
would	O
be	O
hydrolyzed	O
in	O
vivo	O
by	O
carboxylate	O
esterase	O
(	O
E	O
.	O
The	O
antibacterial	O
activity	O
of	O
these	O
derivatives	O
was	O
studied	O
with	O
the	O
finding	O
that	O
the	O
optimal	O
1	O
-	O
and	O
7	O
-	O
position	O
substituents	O
for	O
Gram	O
positive	O
activity	O
are	O
cyclopropyl	O
and	O
4	B-PARTIUPAC
-	I-PARTIUPAC
(	I-PARTIUPAC
2,6	I-PARTIUPAC
-	I-PARTIUPAC
dimethylpyridinyl	I-PARTIUPAC
)	I-PARTIUPAC
,	O
respectively	O
.	O
New	O
1	B-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylurea	I-IUPAC
derivatives	B-MODIFIER
and	O
their	O
1	B-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylthiourea	I-IUPAC
isosteres	B-MODIFIER
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
human	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptor	O
affinity	O
.	O
gondii	O
DHFR	O
.	O
44	O
also	O
inhibited	O
platelet	O
aggregation	O
ex	O
vivo	O
in	O
guinea	O
pigs	O
.	O
Monoiodination	O
of	O
25	O
to	O
yield	O
26	O
and	O
of	O
27	O
to	O
yield	O
28	O
resulted	O
in	O
an	O
additional	O
4	O
-	O
fold	O
increase	O
in	O
affinity	O
at	O
sst1	O
.	O
Of	O
the	O
series	O
studied	O
,	O
the	O
N	B-IUPAC
(	I-IUPAC
1	I-IUPAC
)	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
4,4	I-IUPAC
-	I-IUPAC
triamine	I-IUPAC
system	B-MODIFIER
6	O
had	O
significantly	O
higher	O
IC	O
(	O
50	O
)	O
values	O
(	O
lower	O
cytotoxicity	O
)	O
in	O
the	O
L1210	O
,	O
CHO	O
,	O
and	O
CHO	O
-	O
MG	O
cell	O
lines	O
.	O
6beta	B-IUPAC
-	I-IUPAC
Acyloxy	I-IUPAC
(	I-IUPAC
nor	I-IUPAC
)	I-IUPAC
tropane	I-IUPAC
,	O
two	O
other	O
(	O
nor	O
)	O
tropanes	O
,	O
and	O
the	O
classical	O
muscarinic	O
agonists	O
had	O
higher	O
affinity	O
versus	O
agonist	O
binding	O
compared	O
to	O
antagonist	O
binding	O
for	O
transfected	O
m	O
(	O
4	O
)	O
-	O
receptors	O
.	O
A	O
good	O
correlation	O
was	O
found	O
between	O
the	O
electronic	O
properties	O
of	O
the	O
substituent	O
and	O
the	O
inhibitory	O
activity	O
and	O
stability	O
.	O
The	O
results	O
of	O
these	O
investigations	O
allow	O
certain	O
speculations	O
to	O
be	O
made	O
with	O
respect	O
to	O
the	O
role	O
of	O
the	O
furan	O
ring	O
in	O
the	O
3	B-IUPAC
-	I-IUPAC
arylspiro	I-IUPAC
[	I-IUPAC
isobenzofuran	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
3H	I-IUPAC
)	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
piperidines	I-IUPAC
]	I-IUPAC
and	O
antitetrabenazine	O
activity	O
.	O
The	O
antagonist	O
(	B-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
butylpropylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorotetralin	I-IUPAC
(	O
16	O
)	O
bound	O
with	O
high	O
affinity	O
(	O
Ki	O
=	O
4.4	O
nM	O
)	O
to	O
the	O
DA	O
D3	O
receptor	O
and	O
was	O
the	O
most	O
D3	O
-	O
selective	O
compound	O
(	O
10	O
-	O
fold	O
)	O
.	O
Most	O
of	O
the	O
BTCP	O
homologues	O
displayed	O
greater	O
ability	O
to	O
inhibit	O
[	O
3H	O
]	O
DA	O
uptake	O
in	O
rat	O
forebrain	O
synaptosomes	O
than	O
cocaine	O
.	O
Different	O
substituents	O
were	O
introduced	O
in	O
the	O
1	O
-	O
position	O
of	O
the	O
piperidine	O
ring	O
in	O
the	O
5	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	O
substituted	B-MODIFIER
derivative	I-MODIFIER
.	O
Structure	O
-	O
activity	O
relationships	O
for	O
compounds	O
with	O
the	O
4,6	B-IUPAC
-	I-IUPAC
dimethyloctenoate	I-IUPAC
at	O
C6	O
(	O
S1	O
analogues	O
)	O
were	O
different	O
from	O
those	O
for	O
analogues	O
lacking	O
the	O
C6	O
ester	O
(	O
H1	O
analogues	O
)	O
,	O
with	O
a	O
greater	O
dependence	O
on	O
the	O
nature	O
of	O
the	O
C3	O
-	O
substituent	O
for	O
the	O
H1	O
series	O
.	O
carinii	O
DHFR	O
were	O
the	O
2,5	B-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
(	O
5j	O
)	O
,	O
3	B-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dimethoxybenzyl	I-IUPAC
(	O
5k	O
)	O
,	O
and	O
3,4,5	B-IUPAC
-	I-IUPAC
trimethoxybenzyl	I-IUPAC
(	O
5l	O
)	O
analogues	B-MODIFIER
,	O
with	O
IC50	O
values	O
of	O
0.057	O
,	O
0.10	O
,	O
and	O
0.091	O
microM	O
,	O
respectively	O
.	O
In	O
agreement	O
with	O
these	O
findings	O
,	O
disruption	O
of	O
the	O
protein	O
-	O
protein	O
interaction	O
between	O
uPAR	O
present	O
on	O
tumor	O
cells	O
and	O
its	O
ligand	O
uPA	O
evolved	O
as	O
an	O
attractive	O
intervention	O
strategy	O
to	O
impair	O
tumor	O
growth	O
and	O
metastasis	O
.	O
,	O
its	O
N3	B-IUPAC
-	I-IUPAC
trifluoroacetyl	I-IUPAC
derivative	B-MODIFIER
(	O
4b	O
)	O
,	O
was	O
a	O
good	O
in	O
vivo	O
inhibitor	O
of	O
AlDH	O
,	O
mimicking	O
the	O
activity	O
of	O
the	O
parent	O
N1	B-IUPAC
-	I-IUPAC
ethylchlorpropamide	I-IUPAC
.	O
At	O
60	O
min	O
post	O
-	O
iv	O
-	O
injection	O
,	O
the	O
specific	O
uptakes	O
,	O
as	O
measured	O
by	O
[	O
striatum	O
-	O
cerebellum	O
]	O
/	O
cerebellum	O
(	O
[	O
ST	O
-	O
CB	O
]	O
/	O
CB	O
)	O
ratio	O
,	O
were	O
1.72	O
and	O
2.79	O
for	O
2A	O
,	O
B	O
,	O
respectively	O
.	O
In	O
vitro	O
,	O
5a	O
inhibited	O
SP	O
-	O
induced	O
contraction	O
of	O
isolated	O
guinea	O
pig	O
trachea	O
strips	O
with	O
IC50	O
of	O
2.3	O
x	O
10	O
(	O
-	O
6	O
)	O
M	O
and	O
caused	O
no	O
contraction	O
when	O
used	O
alone	O
in	O
this	O
preparation	O
up	O
to	O
3.2	O
x	O
10	O
(	O
-	O
5	O
)	O
M	O
.	O
The	O
prototypes	O
,	O
belonging	O
to	O
five	O
chemical	O
series	O
,	O
were	O
evaluated	O
for	O
their	O
estrogen	O
receptor	O
affinity	O
and	O
for	O
estrogen	O
agonist	O
-	O
antagonist	O
activities	O
.	O
carinii	O
enzyme	O
and	O
thus	O
were	O
nonselective	O
.	O
Among	O
the	O
thymine	O
,	O
uracil	O
,	O
and	O
5	B-MODIFIER
-	I-MODIFIER
substituted	I-MODIFIER
uracil	B-IUPAC
derivatives	B-MODIFIER
,	O
thymine	O
(	O
alpha	O
-	O
isomer	O
)	O
and	O
uracil	O
(	O
beta	O
-	O
isomer	O
)	O
derivatives	O
exhibited	O
moderate	O
anti	O
-	O
HIV	O
activity	O
.	O
Compound	O
4	O
was	O
also	O
relatively	O
neurotoxic	O
(	O
TD50	O
=	O
124	O
mg	O
/	O
kg	O
)	O
.	O
The	O
stereochemical	O
course	O
of	O
the	O
enzymatic	O
reaction	O
was	O
not	O
significantly	O
altered	O
at	O
glutathione	O
concentrations	O
as	O
low	O
as	O
25	O
microM	O
.	O
In	O
vivo	O
experiments	O
with	O
N	B-IUPAC
-	I-IUPAC
methylacetazolamide	I-IUPAC
suggest	O
that	O
ocular	O
metabolism	O
to	O
acetazolamide	O
was	O
responsible	O
for	O
the	O
observed	O
topical	O
activity	O
.	O
carinii	O
enzyme	O
,	O
with	O
most	O
of	O
the	O
analogues	O
giving	O
IC50	O
values	O
of	O
0.01-0.1	O
microM	O
.	O
as	O
tadpole	O
anesthetics	O
.	O
Sonicated	O
solutions	O
of	O
the	O
conjugates	O
existed	O
in	O
the	O
form	O
of	O
micellar	O
disks	O
(	O
size	O
0.01-0.04	O
microns	O
)	O
.	O
These	O
results	O
clearly	O
demonstrated	O
that	O
an	O
array	O
of	O
simple	O
RGD	O
tripeptides	O
on	O
a	O
NIR	O
fluorescent	O
dye	O
core	O
can	O
be	O
recognized	O
by	O
ABIR	O
.	O
In	O
cloned	O
human	O
nicotinic	O
acetylcholine	O
receptors	O
(	O
nAChR	O
)	O
expressed	O
in	O
Xenopus	O
oocytes	O
,	O
both	O
17c	O
and	O
26	O
activated	O
alpha7	O
and	O
alpha3beta2	O
receptor	O
subtypes	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
but	O
26	O
was	O
clearly	O
the	O
more	O
potent	O
agonist	O
.	O
It	O
has	O
been	O
observed	O
that	O
the	O
presence	O
of	O
a	O
carbomethoxy	O
at	O
position	O
3	O
and	O
an	O
aryl	O
substituent	O
at	O
position	O
1	O
in	O
beta	O
-	O
carbolines	O
effectively	O
enhances	O
antifilarial	O
activity	O
particularly	O
against	O
A	O
.	O
Structure	O
-	O
activity	O
relationships	O
are	O
also	O
considered	O
.	O
Reducing	O
the	O
long	O
acyl	O
chain	O
to	O
an	O
acetyl	O
moiety	O
and	O
attaching	O
a	O
compensating	O
lipophilic	O
chain	O
to	O
the	O
lactone	O
ring	O
as	O
an	O
alpha	B-IUPAC
-	I-IUPAC
alkylidene	I-IUPAC
moiety	B-MODIFIER
produced	O
compounds	O
10e	O
and	O
10f	O
(	O
Z	O
-	O
isomers	O
)	O
and	O
11e	O
and	O
11f	O
(	O
E	O
-	O
isomers	O
)	O
,	O
which	O
were	O
constructed	O
on	O
the	O
more	O
effective	O
5,5	B-IUPAC
-	I-IUPAC
bis	I-IUPAC
(	I-IUPAC
hydroxymethyl	I-IUPAC
)	I-IUPAC
tetrahydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
furanone	I-IUPAC
template	O
.	O
Some	O
of	O
the	O
compounds	O
,	O
in	O
particular	O
S	B-IUPAC
-	I-IUPAC
tubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
propyl	I-IUPAC
ester	I-IUPAC
(	O
36	O
)	O
,	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoroacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
tubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
isopropyl	I-IUPAC
ester	I-IUPAC
(	O
27	O
)	O
,	O
S	B-IUPAC
-	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
deoxytubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
(	O
58	O
)	O
,	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
trifluoracetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
tubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
propyl	I-IUPAC
ester	I-IUPAC
(	O
26	O
)	O
,	O
and	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
methoxyacetyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
S	I-IUPAC
-	I-IUPAC
tubercidinyl	I-IUPAC
-	I-IUPAC
L	I-IUPAC
-	I-IUPAC
homocysteine	I-IUPAC
ethyl	I-IUPAC
ester	I-IUPAC
(	O
31	O
)	O
showed	O
potent	O
and	O
selective	O
activity	O
against	O
HSV	O
,	O
VV	O
,	O
and	O
VSV	O
.	O
31P	O
NMR	O
spectroscopy	O
was	O
used	O
to	O
study	O
the	O
products	O
of	O
the	O
decomposition	O
of	O
the	O
antitumor	O
drug	O
ifosfamide	O
(	O
IF	O
,	O
1d	O
)	O
and	O
its	O
N	B-IUPAC
-	I-IUPAC
dechloroethylated	I-IUPAC
metabolites	B-MODIFIER
,	O
namely	O
,	O
2,3	B-IUPAC
-	I-IUPAC
didechloroethylIF	I-IUPAC
(	O
1a	O
)	O
and	O
2	B-PARTIUPAC
-	I-PARTIUPAC
(	O
1b	O
)	O
and	O
3	B-IUPAC
-	I-IUPAC
dechloroethylIF	I-IUPAC
(	O
1c	O
)	O
,	O
in	O
buffered	O
solutions	O
at	O
acidic	O
pH	O
.	O
The	O
final	O
compound	O
,	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxy	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
butynyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
4'	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
methoxybenzyl	I-IUPAC
]	I-IUPAC
pyrimidine	I-IUPAC
(	O
22	O
)	O
,	O
was	O
both	O
potent	O
and	O
selective	O
against	O
M	O
.	O
This	O
finding	O
supports	O
our	O
previously	O
published	O
hypothesis	O
of	O
different	O
binding	O
modes	O
for	O
pyrrolopyrimidines	O
,	O
such	O
as	O
ADPEP	O
(	O
1	O
)	O
and	O
DPEAP	O
(	O
2	O
)	O
.	O
Amine	O
4	O
retains	O
the	O
dopaminergic	O
pharmacophore	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ethylamine	I-IUPAC
,	O
and	O
the	O
chlorine	O
atom	O
replaces	O
the	O
"	O
para	O
"	O
hydroxyl	B-IUPAC
group	B-MODIFIER
of	O
DA	O
.	O
A	O
direct	O
correlation	O
was	O
observed	O
between	O
polyamine	O
-	O
conjugate	O
uptake	O
and	O
cytotoxicity	O
.	O
Compounds	O
4-6	O
were	O
all	O
inactive	O
against	O
HCMV	O
but	O
exhibited	O
appreciable	O
antiviral	O
activity	O
against	O
VZV	O
.	O
These	O
experiments	O
also	O
indicate	O
that	O
the	O
S	O
enantiomer	O
of	O
6b	O
is	O
a	O
specific	O
ligand	O
(	O
KD	O
=	O
1.2	O
nM	O
)	O
for	O
the	O
D	O
-	O
2	O
receptor	O
.	O
This	O
new	O
orientation	O
was	O
mainly	O
caused	O
by	O
the	O
space	O
filling	O
substitution	O
at	O
the	O
2	O
-	O
position	O
of	O
the	O
imidazole	O
ring	O
and	O
influenced	O
the	O
location	O
of	O
the	O
protonated	O
N	O
(	O
alpha	O
)	O
-	O
atom	O
which	O
was	O
positioned	O
more	O
between	O
TM	O
III	O
and	O
TM	O
VI	O
.	O
Three	O
simple	O
2	B-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
alkyl	I-IUPAC
-	I-IUPAC
5,6,7,8	I-IUPAC
-	I-IUPAC
tetrahydroquinazoline	I-IUPAC
model	B-MODIFIER
compounds	I-MODIFIER
(	O
9a	O
-	O
c	O
)	O
were	O
also	O
prepared	O
in	O
one	O
step	O
from	O
commercially	O
available	O
4	B-IUPAC
-	I-IUPAC
alkylcyclohexanones	I-IUPAC
by	O
this	O
method	O
.	O
Three	O
of	O
10	O
synthesized	O
fluorescent	O
compounds	O
,	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
naphthylmethyl	I-IUPAC
)	I-IUPAC
guanidinium	I-IUPAC
sulfate	I-IUPAC
(	O
1	O
)	O
,	O
1	B-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dibenz	I-IUPAC
[	I-IUPAC
b	I-IUPAC
,	I-IUPAC
f	I-IUPAC
]	I-IUPAC
azepin	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
]	I-IUPAC
guanidinium	I-IUPAC
sulfate	I-IUPAC
(	O
2	O
)	O
,	O
and	O
(	B-IUPAC
2R	I-IUPAC
,	I-IUPAC
3S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2beta	I-IUPAC
-	I-IUPAC
ethoxycarbonyl	I-IUPAC
-	I-IUPAC
3beta	I-IUPAC
-	I-IUPAC
tropanyl	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
naphthalene	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
sulfonate	I-IUPAC
(	O
6	O
)	O
,	O
exhibited	O
high	O
affinity	O
(	O
IC	O
(	O
50	O
)	O
about	O
50	O
nM	O
)	O
for	O
the	O
NET	O
.	O
The	O
presence	O
of	O
the	O
2	B-IUPAC
-	I-IUPAC
propylidene	I-IUPAC
group	B-MODIFIER
at	O
C	O
-	O
5	O
on	O
the	O
5H	B-IUPAC
-	I-IUPAC
dibenzo	I-IUPAC
[	I-IUPAC
a	I-IUPAC
,	I-IUPAC
d	I-IUPAC
]	I-IUPAC
cycloheptene	I-IUPAC
moiety	B-MODIFIER
did	O
not	O
interfere	O
greatly	O
,	O
as	O
compared	O
to	O
clozapine	O
,	O
with	O
the	O
in	O
vitro	O
affinity	O
of	O
this	O
5,11	B-IUPAC
-	I-IUPAC
dicarbo	I-IUPAC
analogue	B-MODIFIER
of	O
clozapine	O
for	O
muscarinic	O
and	O
dopamine	O
D	O
-	O
1	O
and	O
D	O
-	O
2	O
binding	O
sites	O
in	O
rat	O
brain	O
.	O
3,5	O
-	O
Disubstitution	O
and	O
2	O
-	O
substitution	O
led	O
to	O
a	O
decline	O
in	O
activity	O
.	O
A	O
wide	O
range	O
of	O
IC50	O
values	O
were	O
observed	O
for	O
pyranones	O
and	O
thiopyranones	O
substituted	O
at	O
the	O
6	O
-	O
position	O
,	O
with	O
the	O
3	O
-	O
and	O
5	O
-	O
positions	O
proving	O
intolerant	O
to	O
substitution	O
.	O
Among	O
them	O
,	O
the	O
highest	O
activity	O
was	O
observed	O
for	O
the	O
3	B-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
9	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
derivative	B-MODIFIER
rac	O
-	O
28	O
[	O
about	O
15	O
-	O
fold	O
more	O
active	O
than	O
THA	O
and	O
about	O
9	O
-	O
fold	O
more	O
active	O
than	O
(	O
-	O
)	O
-	O
huperzine	O
A	O
]	O
.	O
The	O
reduced	O
slope	O
for	O
the	O
more	O
hydrophilic	O
molecules	O
of	O
the	O
series	O
offers	O
some	O
advantage	O
for	O
this	O
type	O
of	O
hydroxypyridinone	O
as	O
the	O
distribution	O
coefficients	O
for	O
such	O
complexes	O
do	O
not	O
change	O
so	O
rapidly	O
with	O
increasing	O
ligand	O
hydrophilicity	O
.	O
The	O
new	O
compounds	O
of	O
each	O
type	O
were	O
active	O
against	O
aconitine	O
-	O
induced	O
arrhythmia	O
and	O
several	O
of	O
them	O
had	O
higher	O
activity	O
and	O
better	O
chemotherapeutic	O
index	O
than	O
quinidine	O
.	O
An	O
(	B-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N5	I-IUPAC
-	I-IUPAC
alpha	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
(	I-IUPAC
phenylacetyl	I-IUPAC
)	I-IUPAC
derivative	B-MODIFIER
was	O
the	O
most	O
potent	O
derivative	O
at	O
A3	O
receptors	O
,	O
with	O
a	O
Ki	O
value	O
of	O
0.36	O
nM	O
.	O
An	O
I2	O
-	O
catalyzed	O
isomerization	O
of	O
the	O
intermediate	O
9Z	B-IUPAC
-	I-IUPAC
aldehyde	I-IUPAC
yielded	O
the	O
all	B-IUPAC
-	I-IUPAC
E	I-IUPAC
-	I-IUPAC
aldehyde	I-IUPAC
,	O
which	O
was	O
olefinated	O
as	O
above	O
to	O
yield	O
the	O
(	B-PARTIUPAC
all	I-PARTIUPAC
-	I-PARTIUPAC
E	I-PARTIUPAC
)	I-PARTIUPAC
-	I-PARTIUPAC
and	O
(	B-IUPAC
13Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
retinoic	I-IUPAC
acid	I-IUPAC
analogs	B-MODIFIER
of	O
1	O
.	O
The	O
conformation	O
of	O
sulfonyl	B-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
derivatives	B-MODIFIER
,	O
such	O
as	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
chlorophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
benzo	I-IUPAC
[	I-IUPAC
2,1,3	I-IUPAC
]	I-IUPAC
thiadiazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
sulfonyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
N	I-IUPAC
"	I-IUPAC
-	I-IUPAC
hydroxyguanidine	I-IUPAC
(	O
4g	O
)	O
,	O
investigated	O
utilizing	O
HMBC	O
NMR	O
,	O
theoretical	O
calculations	O
,	O
and	O
X	O
-	O
ray	O
crystallography	O
,	O
indicated	O
stacking	O
of	O
the	O
two	O
aromatic	O
rings	O
.	O
Moreover	O
,	O
at	O
the	O
pH	O
of	O
the	O
in	O
vitro	O
assays	O
,	O
2b	O
was	O
very	O
stable	O
with	O
a	O
decomposition	O
(	O
to	O
aldehyde	O
)	O
half	O
-	O
life	O
of	O
&	O
gt	O
;	O
15	O
d	O
.	O
Compound	O
2	O
was	O
the	O
more	O
potent	O
(	O
anti	O
-	O
MES	O
ED50	O
=	O
66	O
mg	O
/	O
kg	O
)	O
,	O
and	O
its	O
in	O
vivo	O
anti	O
-	O
MES	O
effect	O
was	O
consistent	O
with	O
its	O
in	O
vitro	O
potency	O
of	O
binding	O
to	O
the	O
voltage	O
-	O
sensitive	O
sodium	O
channel	O
(	O
IC50	O
=	O
160	O
microM	O
for	O
the	O
inhibition	O
of	O
binding	O
of	O
[	O
3H	O
]	O
BTX	O
-	O
B	O
)	O
,	O
suggesting	O
that	O
2	O
may	O
be	O
a	O
new	O
class	O
I	O
anticonvulsant	O
.	O
These	O
compounds	O
give	O
important	O
insight	O
into	O
the	O
steric	O
and	O
stereochemical	O
preferences	O
of	O
both	O
PNMT	O
and	O
the	O
alpha	O
(	O
2	O
)	O
-	O
adrenoceptor	O
,	O
which	O
should	O
assist	O
in	O
the	O
development	O
of	O
new	O
PNMT	O
inhibitors	O
.	O
The	O
in	O
vivo	O
efficacy	O
of	O
1	B-IUPAC
-	I-IUPAC
cyclopropyl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
fluoro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
fluoromethyl	I-IUPAC
)	I-IUPAC
piperazinyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
oxoquinoline	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
(	O
20	O
)	O
was	O
excellent	O
with	O
better	O
oral	O
absorption	O
than	O
ciprofloxacin	O
(	O
2	O
)	O
.	O
The	O
four	O
corresponding	O
isomers	O
were	O
prepared	O
in	O
which	O
the	O
beta	B-IUPAC
-	I-IUPAC
methylphenylalanine	I-IUPAC
residue	B-MODIFIER
was	O
p	O
-	O
nitro	O
substituted	O
,	O
that	O
is	O
with	O
a	O
beta	B-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
p	I-IUPAC
-	I-IUPAC
nitrophenylalanine	I-IUPAC
(	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe	O
)	O
residue	O
,	O
to	O
give	O
[	O
(	O
2S	O
,	O
3S	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe4	O
]	O
DPDPE	O
(	O
6	O
)	O
,	O
[	O
(	O
2R	O
,	O
3R	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe4	O
]	O
DPDPE	O
(	O
7	O
)	O
,	O
[	O
(	O
2S	O
,	O
3R	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe4	O
]	O
DPDPE	O
(	O
8	O
)	O
,	O
and	O
[	O
(	O
2R	O
,	O
3S	O
)	O
-	O
beta	O
-	O
Me	O
-	O
p	O
-	O
NO2Phe4	O
]	O
DPDPE	O
(	O
9	O
)	O
,	O
respectively	O
.	O
Both	O
a	O
carboxyl	O
group	O
at	O
the	O
7	O
-	O
position	O
and	O
a	O
tetrazole	O
ring	O
at	O
the	O
2'	O
-	O
position	O
were	O
particularly	O
important	O
for	O
potent	O
and	O
orally	O
active	O
AII	O
antagonistic	O
activity	O
and	O
a	O
long	O
-	O
acting	O
hypotensive	O
effect	O
.	O
The	O
results	O
showed	O
stereospecificity	O
of	O
the	O
furnidipine	O
isomers	O
in	O
brain	O
,	O
ileum	O
,	O
and	O
cardiac	O
tissues	O
,	O
the	O
(	O
SS	O
)	O
-	O
and	O
(	O
SR	O
)	O
-	O
isomers	O
clearly	O
being	O
more	O
potent	O
than	O
their	O
(	O
RR	O
)	O
-	O
and	O
(	O
RS	O
)	O
-	O
enantiomers	O
.	O
The	O
AE	O
activity	O
score	O
of	O
2	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
4,5	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
trifluoromethylbenzoyl	I-IUPAC
)	I-IUPAC
thiophene	I-IUPAC
(	O
PD	O
81,723	O
)	O
,	O
which	O
was	O
19%	O
,	O
served	O
as	O
a	O
standard	O
for	O
comparison	O
.	O
Desamination	O
of	O
the	O
N	O
-	O
terminus	O
of	O
17	O
to	O
yield	O
18	O
,	O
on	O
the	O
other	O
hand	O
,	O
resulted	O
in	O
significant	O
loss	O
of	O
affinity	O
.	O
The	O
comparable	O
whole	O
brain	O
and	O
blood	O
half	O
-	O
lives	O
for	O
Me	O
[	O
18F	O
]	O
FBWAY	O
(	O
[	O
18F	O
]	O
4c	O
)	O
were	O
16	O
and	O
18	O
min	O
,	O
respectively	O
.	O
Direct	O
methylation	O
of	O
1	O
with	O
CH3I	O
furnished	O
4	B-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
methylpyrazofurin	I-IUPAC
(	O
6	O
)	O
.	O
The	O
binding	O
profiles	O
of	O
the	O
two	O
selective	O
muscarinic	O
antagonists	O
reveal	O
the	O
complexity	O
and	O
diversity	O
of	O
muscarinic	O
receptor	O
subtypes	O
throughout	O
the	O
brain	O
.	O
Among	O
the	O
synthesized	O
compounds	O
,	O
[	O
Dmt1	O
,	O
d	O
-	O
2	O
-	O
Nal4	O
]	O
endomorphin	O
-	O
1	O
,	O
designated	O
antanal	O
-	O
1	O
,	O
and	O
[	O
Dmt1	O
,	O
d	O
-	O
2	O
-	O
Nal4	O
]	O
endomorphin	O
-	O
2	O
,	O
designated	O
antanal	O
-	O
2	O
,	O
turned	O
out	O
to	O
be	O
highly	O
potent	O
and	O
selective	O
mu	O
-	O
opioid	O
receptor	O
antagonists	O
,	O
as	O
judged	O
on	O
the	O
basis	O
of	O
two	O
functional	O
assays	O
,	O
the	O
receptor	O
binding	O
assay	O
and	O
the	O
hot	O
plate	O
test	O
of	O
analgesia	O
.	O
The	O
biological	O
activity	O
of	O
these	O
arotinoids	O
was	O
determined	O
in	O
the	O
tracheal	O
organ	O
culture	O
assay	O
and	O
compared	O
with	O
trans	O
-	O
retinoic	O
acid	O
for	O
ability	O
to	O
reverse	O
keratinization	O
in	O
vitamin	O
A	O
deficient	O
hamsters	O
.	O
None	O
of	O
the	O
chloro	O
derivatives	O
or	O
oxacyclopentenes	O
exhibited	O
an	O
antiviral	O
effect	O
at	O
noncytotoxic	O
concentrations	O
.	O
Mainly	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
acyloxy	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
esters	I-IUPAC
and	O
1	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
alkoxycarbonyl	I-IUPAC
)	I-IUPAC
oxy	I-IUPAC
]	I-IUPAC
alkyl	I-IUPAC
esters	I-IUPAC
,	O
double	O
ester	O
derivatives	O
,	O
were	O
synthesized	O
.	O
The	O
influence	O
of	O
this	O
group	O
on	O
the	O
biological	O
activity	O
was	O
evaluated	O
by	O
testing	O
the	O
corresponding	O
derivatives	O
20-22	O
in	O
which	O
the	O
4	B-PARTIUPAC
-	I-PARTIUPAC
alkylsemicarbazono	I-PARTIUPAC
moiety	B-MODIFIER
was	O
removed	O
(	O
compound	O
20	O
)	O
or	O
its	O
alkylureido	O
portion	O
shifted	O
at	O
position	O
1	O
(	O
compounds	O
21-22	O
)	O
.	O
This	O
selectivity	O
was	O
more	O
pronounced	O
for	O
9	O
,	O
which	O
showed	O
IC	O
(	O
50	O
)	O
values	O
of	O
40	O
and	O
500	O
microM	O
as	O
an	O
inhibitor	O
of	O
glial	O
and	O
neuronal	O
GABA	O
uptake	O
,	O
respectively	O
.	O
They	O
were	O
also	O
highly	O
effective	O
6	O
h	O
after	O
a	O
50	O
mg	O
/	O
kg	O
oral	O
dose	O
.	O
Since	O
our	O
previous	O
studies	O
with	O
monophenyl	B-IUPAC
-	O
substituted	B-MODIFIER
bicyclic	B-MODIFIER
2,4	B-IUPAC
-	I-IUPAC
oxazolidinediones	I-IUPAC
suggested	O
that	O
N3	O
-	O
alkylation	O
and	O
the	O
conformational	O
constraint	O
of	O
a	O
5	O
-	O
alkyl	O
substituent	O
over	O
one	O
face	O
of	O
the	O
oxazolidinedione	O
ring	O
improved	O
activity	O
,	O
we	O
synthesized	O
two	O
examples	O
of	O
analogous	O
bicyclic	O
hydantoins	O
.	O
Hydrophilicity	O
of	O
these	O
analogues	O
,	O
a	O
potential	O
measure	O
of	O
their	O
ability	O
to	O
be	O
formulated	O
for	O
sustained	O
release	O
,	O
was	O
determined	O
using	O
RP	O
-	O
HPLC	O
at	O
neutral	O
pH	O
yielding	O
analogues	O
with	O
shorter	O
as	O
well	O
as	O
longer	O
retention	O
times	O
.	O
Med.	O
Chem.	O
2002	O
,	O
45	O
,	O
208-218	O
.	O
Other	O
amino	O
acid	O
substitutions	O
in	O
this	O
series	O
,	O
such	O
as	O
those	O
with	O
Amp	O
(	O
25	O
,	O
26	O
)	O
,	O
Orn	O
(	O
27	O
)	O
,	O
or	O
IAmp	O
(	O
29	O
)	O
at	O
position	O
7	O
,	O
were	O
also	O
tolerated	O
but	O
with	O
a	O
2	O
-	O
to	O
3	O
-	O
fold	O
loss	O
of	O
affinity	O
and	O
concomitant	O
loss	O
of	O
selectivity	O
.	O
The	O
predicted	O
binding	O
model	O
for	O
PDBU	O
is	O
the	O
same	O
as	O
that	O
for	O
phorbol	B-IUPAC
-	I-IUPAC
13	I-IUPAC
-	I-IUPAC
acetate	I-IUPAC
in	O
terms	O
of	O
the	O
hydrogen	O
-	O
bonding	O
network	O
and	O
hydrophobic	O
contacts	O
.	O
N	B-MODIFIER
-	I-MODIFIER
Substituted	I-MODIFIER
and	O
unsubstituted	B-MODIFIER
4	B-PARTIUPAC
-	I-PARTIUPAC
chlorobenzene	I-PARTIUPAC
-	I-PARTIUPAC
and	O
4	B-IUPAC
-	I-IUPAC
nitrobenzenesulfonamides	I-IUPAC
were	O
also	O
synthesized	O
,	O
and	O
their	O
biochemical	O
characteristics	O
and	O
in	O
vivo	O
ability	O
to	O
lower	O
IOP	O
when	O
applied	O
topically	O
were	O
determined	O
.	O
Results	O
from	O
this	O
study	O
suggest	O
that	O
the	O
selectivity	O
of	O
1	O
is	O
not	O
solely	O
due	O
to	O
the	O
presence	O
of	O
an	O
acidic	O
hydrogen	O
on	O
the	O
7	B-IUPAC
-	I-IUPAC
aminosulfonyl	I-IUPAC
group	B-MODIFIER
of	O
1	O
but	O
is	O
likely	O
also	O
dependent	O
on	O
some	O
other	O
property	O
(	O
e.g.	O
electron	O
-	O
withdrawing	O
character	O
)	O
of	O
the	O
aminosulfonyl	B-IUPAC
group	B-MODIFIER
.	O
5,11	B-IUPAC
-	I-IUPAC
Dihydro	I-IUPAC
-	I-IUPAC
11	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperazinyl	I-IUPAC
)	I-IUPAC
acetyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
6H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
benzodiazepin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
one	I-IUPAC
[	O
pirenzepine	O
(	O
compound	O
I	O
)	O
]	O
and	O
11	B-IUPAC
-	I-IUPAC
[	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
methyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
piperidinyl	I-IUPAC
]	I-IUPAC
acetyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
5,11	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
6H	I-IUPAC
-	I-IUPAC
pyrido	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
b	I-IUPAC
]	I-IUPAC
[	I-IUPAC
1,4	I-IUPAC
]	I-IUPAC
benzodiazepin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
one	I-IUPAC
[	O
AF	O
-	O
DX	O
116	O
(	O
compound	O
II	O
)	O
]	O
were	O
chosen	O
on	O
the	O
basis	O
of	O
their	O
selectivity	O
for	O
M1	O
and	O
M2	O
muscarinic	O
receptors	O
,	O
respectively	O
,	O
and	O
similarities	O
in	O
chemical	O
structure	O
.	O
The	O
facile	O
reaction	O
of	O
cysteine	O
and	O
glutathione	O
with	O
2	O
might	O
represent	O
a	O
mechanism	O
designed	O
to	O
scavenge	O
the	O
biogenic	O
aldehyde	O
and	O
therefore	O
to	O
prevent	O
its	O
alkylation	O
of	O
key	O
intraneuronal	O
protein	O
nucleophiles	O
.	O
The	O
synthesis	O
of	O
aminoaceto	B-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidides	I-IUPAC
substituted	B-MODIFIER
on	O
the	O
amide	O
nitrogen	O
with	O
2	B-IUPAC
-	I-IUPAC
(	I-IUPAC
diethylamino	I-IUPAC
)	I-IUPAC
ethyl	I-IUPAC
,	O
2	B-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
,	O
2	B-IUPAC
-	I-IUPAC
hydroxyethyl	I-IUPAC
,	O
and	O
2	B-IUPAC
-	I-IUPAC
ethoxyethyl	I-IUPAC
groups	B-MODIFIER
is	O
described	O
.	O
This	O
model	O
will	O
be	O
useful	O
for	O
the	O
prediction	O
of	O
high	O
-	O
affinity	O
ligands	O
at	O
radiolabeled	O
H	O
(	O
1	O
)	O
receptors	O
in	O
mammalian	O
brain	O
.	O
Among	O
the	O
studied	O
compounds	O
,	O
the	O
para	O
-	O
chlorophenyl	O
and	O
para	O
-	O
methylphenyl	O
derivatives	O
were	O
selective	O
substrates	O
of	O
NOS	O
II	O
.	O
General	O
structure	O
-	O
activity	O
relationships	O
reveal	O
that	O
optimal	O
enzyme	O
inhibitory	O
activity	O
is	O
displayed	O
by	O
those	O
compounds	O
possessing	O
the	O
acetic	B-IUPAC
acid	I-IUPAC
moiety	B-MODIFIER
.	O
The	O
analogues	O
3c	O
-	O
e	O
,	O
containing	O
C3	O
alkoxy	O
groups	O
,	O
were	O
an	O
order	O
of	O
magnitude	O
weaker	O
than	O
3b	O
,	O
whereas	O
the	O
additional	O
steric	O
bulk	O
of	O
the	O
alkoxy	O
groups	O
of	O
3f	O
-	O
i	O
or	O
the	O
presence	O
of	O
an	O
acidic	O
hydroxyl	O
group	O
at	O
the	O
3	O
-	O
position	O
of	O
the	O
isoxazole	O
ring	O
of	O
3j	O
prevented	O
interaction	O
with	O
AMPA	O
receptor	O
sites	O
.	O
The	O
2'	B-IUPAC
,	I-IUPAC
3,4	I-IUPAC
'	I-IUPAC
,	I-IUPAC
7	I-IUPAC
-	I-IUPAC
tetraethyl	I-IUPAC
ether	I-IUPAC
derivative	B-MODIFIER
of	O
the	O
flavonol	O
morin	O
,	O
7	O
,	O
displayed	O
a	O
Ki	O
value	O
of	O
4.8	O
microM	O
at	O
human	O
A3	O
receptors	O
and	O
was	O
inactive	O
at	O
rat	O
A1	O
/	O
A2a	O
receptors	O
.	O
From	O
earlier	O
work	O
,	O
we	O
concluded	O
that	O
an	O
l	O
-	O
amino	O
acid	O
at	O
position	O
8	O
and	O
a	O
tyrosine	B-IUPAC
or	O
4	B-IUPAC
-	I-IUPAC
aminophenylalanine	I-IUPAC
substitution	B-MODIFIER
at	O
position	O
7	O
may	O
lead	O
to	O
high	O
sst	O
(	O
4	O
)	O
selectivity	O
.	O
[	O
18F	O
]	O
FBWAY	O
(	O
[	O
18F	O
]	O
4b	O
)	O
showed	O
an	O
early	O
rapid	O
net	O
efflux	O
from	O
the	O
whole	O
brain	O
,	O
clearing	O
with	O
a	O
biological	O
half	O
-	O
life	O
of	O
35	O
min	O
.	O
New	O
1H	B-IUPAC
,	I-IUPAC
3H	I-IUPAC
-	I-IUPAC
pyrimido	I-IUPAC
[	I-IUPAC
2,1	I-IUPAC
-	I-IUPAC
f	I-IUPAC
]	I-IUPAC
purine	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
dione	I-IUPAC
derivatives	B-MODIFIER
of	O
arylpiperazine	O
(	O
11-22	O
)	O
were	O
prepared	O
and	O
evaluated	O
in	O
vitro	O
for	O
their	O
affinity	O
for	O
5	O
-	O
HT	O
(	O
1A	O
)	O
,	O
5	O
-	O
HT	O
(	O
2A	O
)	O
,	O
alpha	O
(	O
1	O
)	O
,	O
and	O
D	O
(	O
2	O
)	O
receptors	O
.	O
The	O
resultant	O
5	B-IUPAC
-	I-IUPAC
deazaaminopterin	I-IUPAC
diesters	I-IUPAC
were	O
saponified	O
to	O
provide	O
the	O
target	O
5	B-IUPAC
-	I-IUPAC
deaza	I-IUPAC
analogues	B-MODIFIER
.	O
Palladium	O
(	O
0	O
)	O
-	O
mediated	O
Suzuki	O
-	O
Miyaura	O
and	O
Heck	O
transformations	O
have	O
been	O
exploited	O
to	O
provide	O
examples	O
of	O
8	B-IUPAC
-	I-IUPAC
methylquino	I-IUPAC
[	I-IUPAC
4,3,2	I-IUPAC
-	I-IUPAC
kl	I-IUPAC
]	I-IUPAC
acridines	I-IUPAC
and	O
8,13	B-IUPAC
-	I-IUPAC
dimethylquino	I-IUPAC
[	I-IUPAC
4,3,2	I-IUPAC
-	I-IUPAC
kl	I-IUPAC
]	I-IUPAC
acridinium	I-IUPAC
iodides	I-IUPAC
bearing	O
bulky	O
saturated	O
(	B-IUPAC
3	I-IUPAC
-	I-IUPAC
acetoxy	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
or	O
(	B-IUPAC
E	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
morpholin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
oxopropenyl	I-IUPAC
substituents	B-MODIFIER
variously	O
in	O
the	O
3	O
-	O
,	O
6	O
-	O
,	O
or	O
10	O
-	O
positions	O
of	O
the	O
pentacyclic	O
nucleus	O
.	O
Adenosine	O
5'	O
-	O
triphosphate	O
(	O
ATP	O
)	O
derivatives	B-MODIFIER
of	O
the	O
types	O
N6	O
-	O
R	O
-	O
ATP	O
[	O
R	O
=	O
(	O
CH2	O
)	O
nNHCOCH2I	O
,	O
(	O
CH2	O
)	O
nNHCO	O
-	O
(	O
CH2	O
)	O
mNHCOCH2I	O
,	O
or	O
(	O
CH2	O
)	O
nCON	O
(	O
Me	O
)	O
(	O
CH2	O
)	O
mN	O
(	O
Me	O
)	O
CO	O
(	O
CH2	O
)	O
nNHCOCH2I	O
]	O
,	O
N6	O
-	O
Me	O
-	O
N6	O
-	O
R	O
-	O
ATP	O
[	O
R	O
=	O
(	O
CH2	O
)	O
nN	O
-	O
(	O
Me	O
)	O
CO	O
(	O
CH2	O
)	O
mNHCOCH2I	O
]	O
,	O
and	O
8	O
-	O
R	O
-	O
ATP	O
[	O
R	O
=	O
NM	O
(	O
CH2	O
)	O
nNHCOCH2I	O
]	O
with	O
5	O
-	O
-	O
19	O
spacer	O
atoms	O
between	O
N6	O
or	O
C	O
-	O
8	O
and	O
iodine	O
have	O
been	O
evaluated	O
as	O
potential	O
exo	O
-	O
ATP	O
-	O
site	O
-	O
directed	O
reagents	O
for	O
phosphokinases	O
.	O
This	O
suggests	O
the	O
requirement	O
of	O
an	O
aza	O
atom	O
in	O
the	O
7	O
-	O
but	O
not	O
the	O
5	O
-	O
position	O
(	O
i.e.	O
,	O
a	O
carbon	O
atom	O
in	O
the	O
5	O
-	O
position	O
)	O
for	O
the	O
enhanced	O
potency	O
shown	O
by	O
6	O
-	O
N	O
-	O
methylated	O
derivatives	O
in	O
each	O
series	O
.	O
Replacement	O
of	O
the	O
3	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
group	B-MODIFIER
by	O
chlorine	O
affords	O
the	O
potent	O
but	O
nonselective	O
3	B-IUPAC
-	I-IUPAC
chloro	I-IUPAC
derivatives	B-MODIFIER
6a	O
-	O
k	O
showing	O
similar	O
toxicities	O
under	O
both	O
aerobic	O
and	O
hypoxic	O
conditions	O
.	O
The	O
strongest	O
inhibitor	O
,	O
the	O
[	B-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
4a	I-IUPAC
,	I-IUPAC
10a	I-IUPAC
-	I-IUPAC
dihydrophenothiazin	I-IUPAC
-	I-IUPAC
10	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
]	I-IUPAC
(	I-IUPAC
3	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
dichlorobenzyl	I-IUPAC
)	I-IUPAC
dimethylammonium	I-IUPAC
derivative	B-MODIFIER
(	O
K	O
(	O
i	O
)	O
0.12	O
microM	O
)	O
,	O
was	O
approximately	O
2	O
orders	O
of	O
magnitude	O
more	O
inhibitory	O
than	O
the	O
parent	O
chlorpromazine	O
.	O
The	O
reduction	O
of	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
in	O
the	O
brain	O
has	O
been	O
measured	O
in	O
dementia	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
and	O
dementia	O
with	O
Lewy	O
bodies	O
using	O
(	O
11	O
)	O
C	O
-	O
labeled	O
acetylcholine	O
analogues	O
,	O
N	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
11	I-IUPAC
)	I-IUPAC
C	I-IUPAC
]	I-IUPAC
methylpiperidin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
acetate	I-IUPAC
and	O
propionate	O
,	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
Iodothien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
was	O
used	O
as	O
starting	O
material	O
for	O
the	O
synthesis	O
of	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylthien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
vinylthien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
,	O
and	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
5	I-IUPAC
-	I-IUPAC
ethynylthien	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
.	O
Treatment	O
of	O
7	O
with	O
bromine	O
afforded	O
4	B-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
bromo	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2,3,5	I-IUPAC
-	I-IUPAC
tri	I-IUPAC
-	I-IUPAC
O	I-IUPAC
-	I-IUPAC
benzyl	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyl	I-IUPAC
)	I-IUPAC
pyrrolo	I-IUPAC
[	I-IUPAC
2,3	I-IUPAC
-	I-IUPAC
d	I-IUPAC
]	I-IUPAC
pyridazin	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
one	I-IUPAC
hydrobromide	I-IUPAC
(	O
9	O
)	O
.	O
Antimalarial	O
activity	O
was	O
general	O
among	O
the	O
N2	B-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
N4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
dialkylamino	I-IUPAC
)	I-IUPAC
alkyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2,4	I-IUPAC
-	I-IUPAC
quinazolinediamines	I-IUPAC
(	O
VI	O
)	O
,	O
while	O
the	O
reverse	O
isomers	O
were	O
of	O
lower	O
activity	O
.	O
While	O
10	O
was	O
equipotent	O
with	O
histamine	O
(	O
1	O
)	O
,	O
methylhistaprodifen	O
(	O
13	O
)	O
and	O
dimethylhistaprodifen	O
(	O
14	O
)	O
exceeded	O
the	O
functional	O
potency	O
of	O
1	O
by	O
a	O
factor	O
of	O
3-5	O
(	O
13	O
)	O
and	O
2-3	O
(	O
14	O
)	O
.	O
It	O
is	O
interesting	O
to	O
note	O
that	O
such	O
a	O
small	O
modification	O
in	O
the	O
sugar	O
moiety	O
of	O
active	O
anti	O
-	O
HIV	O
nucleosides	O
(	O
i.e.	O
,	O
displacement	O
of	O
hydrogen	O
by	O
fluorine	O
)	O
almost	O
completely	O
inactivate	O
the	O
agents	O
.	O
These	O
compounds	O
have	O
MGMT	O
inhibitor	O
constants	O
(	O
IC	O
(	O
50	O
)	O
values	O
)	O
of	O
0.8	O
and	O
0.45	O
microM	O
for	O
ITGG	O
and	O
IBGG	O
,	O
respectively	O
,	O
as	O
determined	O
in	O
HeLa	O
S3	O
cells	O
after	O
2	O
-	O
h	O
incubation	O
with	O
inhibitor	O
.	O
The	O
results	O
of	O
this	O
study	O
further	O
demonstrate	O
the	O
possibility	O
of	O
tuning	O
the	O
selectivity	O
of	O
tropane	O
analogues	O
toward	O
the	O
SERT	O
or	O
NET	O
binding	O
site	O
.	O
8	B-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
Ribofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
,	O
8	B-IUPAC
-	I-IUPAC
(	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
arabinofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
,	O
and	O
8	B-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
-	I-IUPAC
deoxy	I-IUPAC
-	I-IUPAC
beta	I-IUPAC
-	I-IUPAC
D	I-IUPAC
-	I-IUPAC
erythro	I-IUPAC
-	I-IUPAC
pentofuranosyl	I-IUPAC
)	I-IUPAC
adenine	I-IUPAC
,	O
as	O
well	O
as	O
compound	O
6	O
,	O
showed	O
no	O
antimalarial	O
activity	O
.	O
The	O
stereoisomer	O
6	O
,	O
but	O
not	O
7	O
,	O
activated	O
cloned	O
AMPA	O
receptor	O
subunits	O
GluR1o	O
,	O
GluR3o	O
,	O
and	O
GluR4o	O
with	O
EC	O
(	O
50	O
)	O
values	O
in	O
the	O
range	O
4.5-15	O
microM	O
and	O
the	O
coexpressed	O
kainate	O
-	O
preferring	O
subunits	O
GluR6	O
+	O
KA2	O
(	O
EC	O
(	O
50	O
)	O
=	O
6.4	O
microM	O
)	O
.	O
The	O
highest	O
selectivity	O
achieved	O
in	O
this	O
limited	O
series	O
was	O
with	O
2,4	B-IUPAC
-	I-IUPAC
diamino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
[	I-IUPAC
N	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3'	I-IUPAC
,	I-IUPAC
4'	I-IUPAC
,	I-IUPAC
5'	I-IUPAC
-	I-IUPAC
trimethoxybenzyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
N	I-IUPAC
-	I-IUPAC
methylamino	I-IUPAC
]	I-IUPAC
quinazoline	I-IUPAC
(	O
17	O
)	O
against	O
T	O
.	O
4	B-IUPAC
-	I-IUPAC
Methyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
phenylsulfonyl	I-IUPAC
)	I-IUPAC
furoxan	I-IUPAC
(	O
10a	O
)	O
,	O
one	O
of	O
the	O
most	O
active	O
derivatives	O
,	O
inhibits	O
the	O
AA	O
-	O
induced	O
increase	O
of	O
cytosolic	O
free	O
Ca2+	O
and	O
production	O
of	O
malondialdehyde	O
.	O
The	O
2	B-IUPAC
-	I-IUPAC
aminoethyl	I-IUPAC
derivatives	B-MODIFIER
were	O
prepared	O
by	O
treatment	O
of	O
N	B-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
phthalimidoethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
,	I-IUPAC
6'	I-IUPAC
-	I-IUPAC
xylidine	I-IUPAC
with	O
chloroacetyl	O
chloride	O
,	O
followed	O
by	O
treatment	O
with	O
either	O
potassium	O
phthalmide	O
or	O
diethylamine	O
.	O
Chemical	O
and	O
biological	O
similarities	O
of	O
plutonium	O
(	O
IV	O
)	O
and	O
iron	O
(	O
III	O
)	O
suggested	O
that	O
octadentate	O
ligands	O
containing	O
hydroxamate	O
or	O
catecholate	O
functional	O
groups	O
,	O
which	O
are	O
found	O
in	O
microbial	O
iron	O
chelating	O
agents	O
(	O
siderophores	O
)	O
,	O
would	O
be	O
effective	O
and	O
relatively	O
selective	O
complexing	O
agents	O
for	O
actinide	O
(	O
IV	O
)	O
ions	O
.	O
By	O
comparison	O
,	O
ciprofloxacin	O
and	O
aminopyrrolidine	O
28	O
gave	O
values	O
of	O
0.25	O
and	O
0.015	O
microgram	O
/	O
mL	O
,	O
respectively	O
,	O
against	O
this	O
organism	O
.	O
The	O
sugar	O
moiety	O
of	O
nucleosides	O
in	O
solution	O
is	O
known	O
to	O
exist	O
in	O
a	O
rapid	O
dynamic	O
equilibrium	O
between	O
extreme	O
Northern	O
and	O
Southern	O
conformations	O
as	O
defined	O
in	O
the	O
pseudorotational	O
cycle	O
.	O
Oral	O
activity	O
was	O
detected	O
in	O
diethyl	B-IUPAC
N	I-IUPAC
,	I-IUPAC
N'	I-IUPAC
-	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
cyano	I-IUPAC
-	I-IUPAC
m	I-IUPAC
-	I-IUPAC
phenylene	I-IUPAC
)	I-IUPAC
dioxamate	I-IUPAC
(	O
compound	O
38	O
)	O
at	O
levels	O
of	O
drug	O
as	O
low	O
as	O
0.1	O
mg	O
/	O
kg	O
.	O
Compounds	O
1a	O
-	O
c	O
and	O
some	O
of	O
their	O
hydrolytic	O
degradation	O
products	O
(	O
4b	O
-	O
1	O
,	O
4b	O
-	O
2	O
,	O
diphosphoric	O
diester	O
[	O
Cl	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
2	O
)	O
NH	O
(	O
CH	O
(	O
2	O
)	O
)	O
(	O
3	O
)	O
OP	O
(	O
O	O
)	O
(	O
OH	O
)	O
]	O
(	O
2	O
)	O
O	O
(	O
5	O
)	O
,	O
and	O
chloroethylamine	O
)	O
did	O
not	O
exhibit	O
,	O
as	O
expected	O
,	O
any	O
antitumor	O
efficacy	O
in	O
vivo	O
against	O
P388	O
leukemia	O
.	O
Within	O
the	O
new	O
phenylaminotetralin	O
series	O
,	O
a	O
correlation	O
was	O
found	O
between	O
the	O
ability	O
to	O
stimulate	O
TH	O
and	O
the	O
potency	O
to	O
compete	O
for	O
binding	O
sites	O
labeled	O
by	O
(	B-IUPAC
+	I-IUPAC
/	I-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
N	I-IUPAC
,	I-IUPAC
N	I-IUPAC
-	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
chloro	I-IUPAC
-	I-IUPAC
7	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
1,2,3,4	I-IUPAC
-	I-IUPAC
tetrahydronaphthalene	I-IUPAC
(	O
[	O
3H	O
]	O
(	O
+	O
/	O
-	O
)	O
-	O
4	O
)	O
.	O
Compound	O
1e	O
produced	O
an	O
ILS	O
of	O
71%	O
at	O
100	O
mg	O
/	O
kg	O
per	O
day	O
X	O
5	O
(	O
ip	O
)	O
in	O
BDF	O
mice	O
inoculated	O
ip	O
with	O
10	O
(	O
6	O
)	O
L	O
-	O
1210	O
cells	O
.	O
A	O
new	O
class	O
of	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
1	I-IUPAC
-	I-IUPAC
cyanamido	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
haloethyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridines	I-IUPAC
(	O
4-6	O
)	O
and	O
arabinouridines	O
(	O
7	O
,	O
8	O
)	O
were	O
synthesized	O
by	O
the	O
regiospecific	O
addition	O
of	O
halogenocyanamides	O
(	O
X	O
-	O
NHCN	O
)	O
to	O
the	O
5	B-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
substituent	B-MODIFIER
of	O
the	O
respective	O
5	B-IUPAC
-	I-IUPAC
vinyl	I-IUPAC
-	I-IUPAC
2'	I-IUPAC
-	I-IUPAC
deoxyuridine	I-IUPAC
(	O
2	O
)	O
and	O
2'	B-IUPAC
-	I-IUPAC
arabinouridine	I-IUPAC
(	O
3	O
)	O
.	O
Structure	O
-	O
activity	O
studies	O
compared	O
displacement	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
nicotine	O
binding	O
in	O
mammalian	O
alpha4beta2	O
nAChR	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
imidacloprid	O
binding	O
in	O
Drosophila	O
nAChR	O
.	O
None	O
of	O
the	O
compounds	O
showed	O
significant	O
activity	O
.	O
Compound	O
12	O
exhibited	O
a	O
4	O
-	O
fold	O
enantioselectivity	O
favoring	O
(	O
+	O
)	O
-	O
12	O
.	O
In	O
this	O
paper	O
,	O
we	O
describe	O
the	O
synthesis	O
of	O
a	O
series	O
of	O
novel	O
substituted	B-MODIFIER
4	B-IUPAC
-	I-IUPAC
aryl	I-IUPAC
-	I-IUPAC
6,7	I-IUPAC
-	I-IUPAC
methylenedioxyphthalazin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
(	I-IUPAC
2H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
.	O
Analogues	O
1-14	O
also	O
antagonize	O
the	O
vascular	O
responses	O
to	O
arginine	O
-	O
vasopressin	O
(	O
AVP	O
)	O
and	O
the	O
in	O
vitro	O
oxytocic	O
responses	O
to	O
oxytocin	O
.	O
One	O
compound	O
,	O
(	B-IUPAC
Z	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,1	I-IUPAC
-	I-IUPAC
dichloro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
[	I-IUPAC
4	I-IUPAC
-	I-IUPAC
[	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
dimethylamino	I-IUPAC
)	I-IUPAC
ethoxy	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenyl	I-IUPAC
]	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
methoxyphenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylcyclopropane	I-IUPAC
(	O
7b	O
)	O
,	O
elicited	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
vivo	O
comparable	O
to	O
MER	O
25	O
.	O
This	O
series	O
of	O
compounds	O
were	O
slightly	O
less	O
potent	O
at	O
A2	O
receptors	O
.	O
Prodrugs	O
6b	O
and	O
6c	O
were	O
also	O
prepared	O
by	O
methylation	O
of	O
the	O
respective	O
diamidoximes	O
5b	O
and	O
5d	O
.	O
Although	O
additional	O
nitrogen	O
atoms	O
resulted	O
in	O
decreased	O
affinity	O
at	O
sigma	O
-	O
1	O
and	O
sigma	O
-	O
2	O
subtypes	O
,	O
an	O
increase	O
in	O
selectivity	O
for	O
sigma	O
-	O
2	O
subtypes	O
was	O
evident	O
;	O
the	O
parent	O
3	O
showed	O
greater	O
selectivity	O
for	O
sigma	O
-	O
1	O
subtypes	O
.	O
A	O
series	O
of	O
4	B-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nitro	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	O
substituted	B-MODIFIER
-	O
imidazoles	B-IUPAC
has	O
been	O
synthesized	O
and	O
tested	O
for	O
their	O
ability	O
to	O
selectively	O
radiosensitize	O
hypoxic	O
Chinese	O
hamster	O
cells	O
(	O
V	O
-	O
79	O
)	O
to	O
the	O
lethal	O
effect	O
of	O
radiation	O
.	O
These	O
compounds	O
are	O
,	O
therefore	O
,	O
also	O
suitable	O
for	O
the	O
isolation	O
of	O
V	O
-	O
2	O
vasopressin	O
receptors	O
from	O
mammalian	O
tissues	O
.	O
The	O
N	B-IUPAC
-	I-IUPAC
oxides	I-IUPAC
VIII	O
did	O
not	O
exhibit	O
significant	O
activity	O
against	O
Plasmodium	O
berghei	O
infections	O
in	O
mice	O
.	O
Among	O
the	O
group	O
of	O
ring	O
substituents	O
studied	O
for	O
symmetrical	O
diarylguanidines	O
,	O
an	O
isopropyl	B-IUPAC
group	B-MODIFIER
was	O
preferred	O
at	O
the	O
ortho	O
position	O
and	O
an	O
ethyl	O
group	O
was	O
preferred	O
at	O
the	O
meta	O
position	O
.	O
The	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
5	O
with	O
pcDHFR	O
was	O
also	O
carried	O
out	O
,	O
which	O
corroborated	O
the	O
design	O
rationale	O
and	O
indicated	O
a	O
hydrophobic	O
interaction	O
of	O
the	O
naphthalene	O
ring	O
of	O
5	O
and	O
Phe69	O
of	O
pcDHFR	O
which	O
is	O
responsible	O
,	O
in	O
part	O
,	O
for	O
the	O
more	O
than	O
18	O
-	O
fold	O
selectivity	O
of	O
5	O
for	O
pcDHFR	O
as	O
compared	O
with	O
rat	O
liver	O
DHFR	O
.	O
Indeed	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
hydroxyalkyl	I-IUPAC
)	I-IUPAC
hydroxypyridinones	I-IUPAC
which	O
are	O
known	O
to	O
be	O
rapidly	O
converted	O
to	O
1	B-IUPAC
-	I-IUPAC
(	I-IUPAC
carboxyalkyl	I-IUPAC
)	I-IUPAC
hydroxypyridinones	I-IUPAC
are	O
also	O
marginally	O
superior	O
to	O
Deferiprone	O
.	O
A	O
series	O
of	O
secondary	O
and	O
tertiary	O
N	O
-	O
alkyl	O
derivatives	O
of	O
(	B-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
fluorotetralin	I-IUPAC
have	O
been	O
prepared	O
.	O
gondii	O
enzyme	O
were	O
those	O
with	O
an	O
ArCH2	O
-	O
NH	O
or	O
ArNHCH2	O
side	O
chain	O
.	O
Within	O
this	O
compound	O
series	O
,	O
5	B-IUPAC
-	I-IUPAC
(	I-IUPAC
aminocarbonyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1,4	I-IUPAC
-	I-IUPAC
dihydro	I-IUPAC
-	I-IUPAC
2	I-IUPAC
,	I-IUPAC
6	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
-	I-IUPAC
nitrophenyl	I-IUPAC
)	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
,	I-IUPAC
4	I-IUPAC
-	I-IUPAC
diphenylpiperidin	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
propyl	I-IUPAC
)	I-IUPAC
aminocarbonyl	I-IUPAC
)	I-IUPAC
pyridine	I-IUPAC
(	O
19	O
)	O
displayed	O
good	O
binding	O
affinity	O
and	O
selectivity	O
for	O
the	O
alpha1a	O
adrenoceptor	O
(	O
pKi	O
=	O
8.73	O
)	O
and	O
potently	O
inhibited	O
(	O
pA2	O
=	O
9.23	O
)	O
phenylephrine	O
-	O
induced	O
contraction	O
of	O
the	O
human	O
prostate	O
.	O
The	O
first	O
involved	O
substitution	O
of	O
the	O
N1	O
-	O
position	O
while	O
the	O
second	O
involved	O
substitution	O
of	O
the	O
N5	O
-	O
position	O
.	O
The	O
order	O
of	O
the	O
inhibitory	O
potency	O
was	O
S	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
S	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
glutathione	I-IUPAC
=	O
S	B-IUPAC
-	I-IUPAC
benzylglutathione	I-IUPAC
greater	O
than	O
S	B-IUPAC
-	I-IUPAC
[	I-IUPAC
(	I-IUPAC
R	I-IUPAC
)	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
phenylethyl	I-IUPAC
]	I-IUPAC
glutathione	I-IUPAC
greater	O
than	O
S	B-IUPAC
-	I-IUPAC
methylglutathione	I-IUPAC
.	O
The	O
6	B-IUPAC
-	I-IUPAC
demethoxyacronycine	I-IUPAC
derivatives	B-MODIFIER
were	O
found	O
to	O
be	O
inactive	O
,	O
whereas	O
in	O
contrast	O
,	O
all	O
of	O
the	O
acronycine	O
derivatives	O
were	O
more	O
potent	O
than	O
acronycine	O
itself	O
when	O
tested	O
against	O
L1210	O
cells	O
in	O
vitro	O
.	O
Analogous	O
peptides	O
with	O
a	O
tyrosine	O
at	O
position	O
11	O
(	O
31-36	O
)	O
were	O
less	O
selective	O
than	O
the	O
corresponding	O
peptides	O
with	O
a	O
tyrosine	O
at	O
position	O
2	O
.	O
Inhibitory	O
potency	O
of	O
the	O
unsubstituted	B-MODIFIER
aza	B-IUPAC
-	I-IUPAC
5	I-IUPAC
[	I-IUPAC
H	I-IUPAC
]	I-IUPAC
-	I-IUPAC
phenanthridin	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
(	O
i.e.	O
,	O
benzonaphthyridones	O
)	O
was	O
dependent	O
on	O
the	O
position	O
of	O
the	O
nitrogen	O
atom	O
within	O
the	O
core	O
structure	O
.	O
In	O
this	O
paper	O
,	O
it	O
is	O
hypothesized	O
that	O
the	O
distinction	O
between	O
certain	O
active	O
and	O
inactive	O
cannabinoids	O
is	O
that	O
the	O
inactive	O
analogs	O
possess	O
extra	O
volume	O
associated	O
with	O
their	O
carbocyclic	O
rings	O
that	O
may	O
be	O
responsible	O
for	O
an	O
unfavorable	O
interaction	O
at	O
the	O
cannabinoid	O
receptor	O
.	O
However	O
,	O
since	O
the	O
in	O
vitro	O
metabolic	O
stability	O
of	O
these	O
analogues	O
was	O
insufficient	O
compared	O
with	O
that	O
of	O
2	O
,	O
further	O
derivatization	O
was	O
performed	O
by	O
introducing	O
an	O
appropriate	O
hydrophilic	O
group	O
into	O
the	O
phenyl	B-IUPAC
or	O
2	B-IUPAC
-	I-IUPAC
pyridyl	I-IUPAC
ring	B-MODIFIER
.	O
(	B-IUPAC
5	I-IUPAC
-	I-IUPAC
Amino	I-IUPAC
-	I-IUPAC
1,3	I-IUPAC
-	I-IUPAC
dimethyl	I-IUPAC
-	I-IUPAC
1H	I-IUPAC
-	I-IUPAC
pyrazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
(	I-IUPAC
2	I-IUPAC
-	I-IUPAC
fluorophenyl	I-IUPAC
)	I-IUPAC
methanone	I-IUPAC
(	O
2	O
)	O
has	O
a	O
behavioral	O
profile	O
suggestive	O
of	O
antipsychotic	O
activity	O
and	O
gave	O
a	O
positive	O
Ames	O
test	O
result	O
.	O
Tissue	O
distribution	O
studies	O
revealed	O
that	O
a	O
number	O
of	O
radioiodinated	O
guanidines	O
showed	O
pronounced	O
localization	O
in	O
the	O
adrenal	O
medullae	O
following	O
intravenous	O
injection	O
,	O
in	O
certain	O
cases	O
exceeding	O
that	O
of	O
either	O
(	B-IUPAC
-	I-IUPAC
)	I-IUPAC
-	I-IUPAC
[	I-IUPAC
3H	I-IUPAC
]	I-IUPAC
norepinephrine	I-IUPAC
or	O
[	B-IUPAC
14C	I-IUPAC
]	I-IUPAC
guanethidine	I-IUPAC
.	O
The	O
reaction	O
of	O
4	B-IUPAC
(	I-IUPAC
5	I-IUPAC
)	I-IUPAC
-	I-IUPAC
iodo	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
4	I-IUPAC
)	I-IUPAC
-	I-IUPAC
nitroimidazole	I-IUPAC
with	O
1,2	B-IUPAC
-	I-IUPAC
epoxy	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
methoxypropane	I-IUPAC
and	O
ethyl	B-IUPAC
alpha	I-IUPAC
-	I-IUPAC
chloroacetate	I-IUPAC
produced	O
two	O
isomeric	O
products	O
in	O
each	O
case	O
,	O
which	O
were	O
identified	O
by	O
their	O
NMR	O
spectra	O
.	O
AMPA	O
(	O
7	O
)	O
and	O
the	O
higher	O
homologue	O
of	O
homo	O
-	O
AMPA	O
(	O
8	O
)	O
,	O
(	B-IUPAC
RS	I-IUPAC
)	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
amino	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
(	I-IUPAC
3	I-IUPAC
-	I-IUPAC
hydroxy	I-IUPAC
-	I-IUPAC
5	I-IUPAC
-	I-IUPAC
methylisoxazol	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
)	I-IUPAC
pentanoic	I-IUPAC
acid	I-IUPAC
(	O
9	O
)	O
,	O
showed	O
relatively	O
weak	O
agonist	O
effects	O
at	O
mGlu6	O
.	O
3	B-IUPAC
-	I-IUPAC
Ethylaminomethyl	I-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
methyl	I-IUPAC
-	I-IUPAC
4	I-IUPAC
(	I-IUPAC
1H	I-IUPAC
)	I-IUPAC
-	I-IUPAC
quinolone	I-IUPAC
(	O
1a	O
)	O
and	O
its	O
6	O
-	O
CH3	O
,	O
6	O
-	O
OCH3	O
,	O
and	O
7	O
-	O
Cl	O
derivatives	O
were	O
prepared	O
by	O
means	O
of	O
the	O
Mannich	O
reaction	O
.	O
Replacement	O
of	O
pyroglutamic	O
acid	O
by	O
pyro	B-IUPAC
-	I-IUPAC
2	I-IUPAC
-	I-IUPAC
aminoadipic	I-IUPAC
acid	I-IUPAC
,	O
2	B-IUPAC
-	I-IUPAC
oxoimidazolidine	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
or	O
gamma	B-IUPAC
-	I-IUPAC
butyrolactone	I-IUPAC
-	I-IUPAC
gamma	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
and	O
that	O
of	O
proline	O
by	O
pipecolic	O
acid	O
,	O
thiazolidine	B-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
carboxylic	I-IUPAC
acid	I-IUPAC
,	O
or	O
homoproline	O
in	O
[	O
Leu2	O
]	O
-	O
and	O
[	O
Nva2	O
]	O
TRH	O
led	O
to	O
tripeptides	O
structurally	O
widely	O
different	O
from	O
TRH	O
.	O
Recombinant	O
NOS	O
I	O
and	O
NOS	O
III	O
also	O
oxidize	O
several	O
N	B-MODIFIER
-	I-MODIFIER
aryl	I-MODIFIER
N'	B-IUPAC
-	I-IUPAC
hydroxyguanidines	I-IUPAC
with	O
the	O
formation	O
of	O
NO	O
,	O
with	O
a	O
clearly	O
different	O
substrate	O
specificity	O
.	O
Extended	O
libraries	O
exploring	O
the	O
6	O
-	O
position	O
of	O
2	B-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
and	O
2	B-IUPAC
-	I-IUPAC
morpholino	I-IUPAC
-	I-IUPAC
thiopyrano	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
ones	I-IUPAC
identified	O
the	O
first	O
highly	O
potent	O
and	O
selective	O
ATM	O
inhibitor	O
2	B-IUPAC
-	I-IUPAC
morpholin	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
6	I-IUPAC
-	I-IUPAC
thianthren	I-IUPAC
-	I-IUPAC
1	I-IUPAC
-	I-IUPAC
yl	I-IUPAC
-	I-IUPAC
pyran	I-IUPAC
-	I-IUPAC
4	I-IUPAC
-	I-IUPAC
one	I-IUPAC
(	O
151C	O
;	O
ATM	O
;	O
IC50	O
=	O
13	O
nM	O
)	O
and	O
revealed	O
constrained	O
SARs	O
for	O
ATM	O
inhibition	O
compared	O
with	O
DNA	O
-	O
PK	O
.	O
Substrate	O
enantioselectivity	O
in	O
the	O
conjugation	O
of	O
phenethyl	O
halides	O
catalyzed	O
by	O
the	O
glutathione	O
S	O
-	O
transferases	O
was	O
studied	O
with	O
partially	O
purified	O
isozymes	O
from	O
rat	O
liver	O
.	O
In	O
conclusion	O
,	O
the	O
1	B-IUPAC
-	I-IUPAC
benzhydryl	I-IUPAC
-	I-IUPAC
3	I-IUPAC
-	I-IUPAC
phenylurea	I-IUPAC
scaffold	B-MODIFIER
seems	O
to	O
be	O
a	O
new	O
interesting	O
template	O
of	O
CB1	O
cannabinoid	O
receptor	O
inverse	O
agonists	O
.	O
This	O
represented	O
the	O
first	O
demonstration	O
of	O
the	O
stereoselective	O
product	O
inhibition	O
of	O
the	O
glutathione	O
S	O
-	O
transferases	O
.	O
